Supporting Information

The Biostructural Features of Additional Jasplakinolide Analogues

Katharine R. Watts,[†] *Brandon Morinaka,*[†] *Taro Amagata,*[†] *Sarah J. Robinson,*[†] *Karen Tenney,*[†] *Walter M. Bray,*[†,‡] *Nadine C. Gassner,*[†,‡] *R. Scott Lokey,*[†,‡] *Joseph Media,*[§] *Frederick A. Valeriote,*[§] *Phillip Crews*[†*]

[†]*Department of Chemistry and Biochemistry and* [‡]*UCSC Chemical Screening Center, University of California, Santa Cruz, Santa Cruz, CA 95064*

[§]*Department of Internal Medicine, Division of Hematology and Oncology, Henry Ford Hospital, Detroit MI 48202*

Index:

University of California, Santa Cruz.
[*]To whom correspondence should be addressed: Phone: 831-459-2603 Fax 831-459-2935 Email: phil@chemistry.ucsc.edu.

Figure S1. NOE correlations of **8** in $CDCl_3$ and DMSO-d_6

A



B



A. NOE in $CDCl_3$
B. Blowup of ^1H spectra region in $CDCl_3$ containing N*H*-Tyr, H-23, and H-26.

C



D



C. NOE in DMSO-d_6

D. Blowup of ^{1}H spectra region in DMSO-d_6 containing N*H*-Tyr, H-23, N*H*-Ala and H-26.

Figure S2. ^{13}C chemical shift differences of the hydroxy-aryl substructures.



Figure S3. Likely pathways for the origin of **9-11** from **1**, and **15** and **12** from **14**.



Figure S4. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **7** in CD_3OD.






20
30
40
50
60
70
80
90
100
110
120
130
8.0
7.5
7.0
6.5
6.0
5.5
5.0
1.5
1.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5


20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5

Figure S5. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **8** in CD_3OD.






0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5


20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5

Figure S6. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **9** in CD_3OD.






7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5



Figure S7. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **10** in CD_3OD.




29
31
30
32
33
20
13
34
9
2
10
14
7
35
3
5
15
26
28
21
18
23
24
25
17
22
11
16
12
27
19
4
1
6
8





Figure S8. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **11** in CD_3OD.




8
6
1
4
19
27
12
16
11
17
22
25
24
23
18
26
28
21
15
35
5
3
14
7
10
9
2
34
13
20
33
32
30
36
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20




20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5

Figure S9. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **12** in CD_3OD.




29
31
30
32
33
20
13
34
9
10
14
7
5
15
26
28
21
24
23
25
22
11
12
27
6
4
8
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180


10
20
30
40
50
60
70
80
90
100
110
120
130
140
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0


10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5

Figure S10. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **13** in CD_3OD.









Figure S11. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **14** in CD_3OD.






7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
10
20
30
40
50
60
70
80
90
100
110
120
130
140


20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5

Figure S12. ^{1}H, ^{13}C, gHMQC, and gHMBC spectra for **15** in $CDCl_3$.




3
8
6
4
1
19
18'
27
12
16
11
22
17
25
24
23
18
17
21
26
28
15
5
2
7
14
10
9
34
13
20
33
32
30
29
31
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20


10
20
30
40
50
60
70
80
90
100
110
120
130
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0


10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5

Table S1. NCI 60-cell line results for **1**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : 613009 / 10	Experiment ID : 9704SR27	Test Type : 08	Units : Molar
Report Date : February 24, 2010	Test Date : April 14, 1997	QNS :	MC :
COMI : Jasplakinolide	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration												
	Time		Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.419	1.454	1.025	0.604	0.568	0.585	0.528	59	18	14	16	11	1.62E-8	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.566	1.526	1.056	0.430	0.420	0.407	0.382	51	-24	-26	-28	-33	1.03E-8	4.78E-8	> 1.00E-4
K-562	0.180	0.896	0.580	0.506	0.467	0.217	0.181	56	45	40	5	.	3.64E-8	> 1.00E-4	> 1.00E-4
RPMI-8226	0.610	0.762	0.510	0.524	0.462	0.353	0.317	-16	-14	-24	-42	-48	< 1.00E-8	< 1.00E-8	> 1.00E-4
SR	0.568	0.927	0.901	0.762	0.598	0.537	0.470	93	54	8	-6	-17	1.23E-7	3.99E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.433	1.836	1.769	0.631	0.527	0.478	0.409	95	14	7	3	-6	3.61E-8	2.33E-5	> 1.00E-4
EKVX	0.325	0.820	0.792	0.510	0.326	0.312	0.312	94	37	.	-4	-4	6.01E-8	1.06E-6	> 1.00E-4
HOP-62	0.219	0.649	0.715	0.301	0.181	0.188	0.191	115	19	-17	-14	-13	4.77E-8	3.33E-7	> 1.00E-4
HOP-92	0.193	1.095	1.113	0.560	0.539	0.565	0.559	102	41	38	41	41	7.05E-8	> 1.00E-4	> 1.00E-4
NCI-H226	0.461	0.921	0.919	0.271	0.205	0.200	0.171	99	-41	-56	-57	-63	2.25E-8	5.09E-8	4.11E-7
NCI-H23	0.779	1.482	1.528	1.233	0.835	0.734	0.412	107	65	8	-6	-47	1.81E-7	3.80E-6	> 1.00E-4
NCI-H322M	0.239	0.790	0.728	0.449	0.308	0.233	0.239	89	38	12	-3	.	5.82E-8	6.79E-6	> 1.00E-4
NCI-H460	0.229	1.794	1.137	0.564	0.538	0.481	0.336	58	21	20	16	7	1.65E-8	> 1.00E-4	> 1.00E-4
NCI-H522	0.279	0.660	0.586	0.303	0.250	0.234	0.182	81	6	-11	-16	-35	2.57E-8	2.33E-7	> 1.00E-4
Colon Cancer															
COLO 205	0.117	0.591	0.398	0.214	0.200	0.218	0.193	59	20	18	21	16	1.73E-8	> 1.00E-4	> 1.00E-4
HCC-2998	0.001	0.642	0.473	0.287	0.251	0.240	0.200	74	45	39	37	31	6.52E-8	> 1.00E-4	> 1.00E-4
HCT-116	0.143	1.477	1.237	0.484	0.217	0.218	0.101	82	26	6	6	-29	3.70E-8	1.44E-5	> 1.00E-4
HCT-15	0.773	1.630	1.565	1.036	0.756	0.781	0.787	92	31	-2	1	2	4.87E-8	.	> 1.00E-4
HT29	0.221	1.201	0.774	0.282	0.253	0.250	0.209	56	6	3	3	-5	1.34E-8	2.28E-5	> 1.00E-4
KM12	0.280	1.459	1.257	0.926	0.666	0.473	0.204	83	55	33	16	-27	1.65E-7	2.37E-5	> 1.00E-4
SW-620	0.281	1.291	0.919	0.723	0.652	0.580	0.431	63	44	37	30	15	4.76E-8	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.190	0.669	0.699	0.205	0.169	0.148	0.141	106	3	-11	-22	-26	3.52E-8	1.66E-7	> 1.00E-4
SF-295	0.430	1.390	1.335	0.691	0.345	0.235	0.318	94	27	-20	-45	-26	4.57E-8	3.81E-7	> 1.00E-4
SF-539	0.209	0.660	0.647	0.151	0.093	0.083	0.110	97	-28	-56	-60	-47	2.38E-8	5.97E-8	.
SNB-19	0.914	1.441	1.431	0.512	0.276	0.299	0.376	98	-44	-70	-67	-59	2.18E-8	4.90E-8	1.71E-7
SNB-75	0.340	0.695	0.601	0.312	0.222	0.131	0.192	74	-8	-35	-62	-44	1.94E-8	7.93E-8	.
U251	0.642	2.465	2.097	1.461	0.764	0.758	0.634	80	45	7	6	-1	7.14E-8	6.73E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.124	0.922	0.265	0.104	0.091	0.073	0.069	18	-16	-27	-41	-44	< 1.00E-8	3.33E-8	> 1.00E-4
M14	0.165	0.796	0.681	0.354	0.254	0.233	0.169	82	30	14	11	1	4.11E-8	> 1.00E-4	> 1.00E-4
MDA-MB-435	0.664	2.725	2.619	1.193	0.896	0.813	0.517	95	26	11	7	-22	4.45E-8	1.77E-5	> 1.00E-4
SK-MEL-2	0.318	0.692	0.626	0.426	0.309	0.130	0.162	82	29	-3	-59	-49	4.03E-8	8.15E-7	.
SK-MEL-28	0.592	1.848	1.787	0.771	0.734	0.847	0.572	95	14	11	20	-3	3.61E-8	7.15E-5	> 1.00E-4
UACC-257	0.710	1.932	1.938	1.633	1.059	1.016	0.630	100	75	29	25	-11	3.49E-7	4.88E-5	> 1.00E-4
UACC-62	0.680	1.705	1.691	1.003	0.866	0.738	0.447	99	31	18	6	-34	5.30E-8	1.39E-5	> 1.00E-4
Ovarian Cancer															
IGROV1	0.276	0.788	0.643	0.157	0.163	0.175	0.191	72	-43	-41	-37	-31	1.54E-8	4.21E-8	> 1.00E-4
OVCAR-3	0.498	1.488	1.421	0.730	0.469	0.252	0.389	93	23	-6	-49	-22	4.17E-8	6.37E-7	> 1.00E-4
OVCAR-4	0.238	1.162	1.108	0.875	0.510	0.237	0.224	94	69	29	.	-6	3.01E-7	9.68E-6	> 1.00E-4
OVCAR-5	0.292	0.831	0.860	0.577	0.472	0.449	0.460	105	53	33	29	31	1.42E-7	> 1.00E-4	> 1.00E-4
OVCAR-8	0.233	0.962	0.968	0.273	0.096	0.017	0.091	101	5	-59	-93	-61	3.41E-8	1.22E-7	7.25E-7
NCI/ADR-RES	0.236	0.643	0.568	0.417	0.310	0.139	0.126	82	44	18	-41	-47	7.06E-8	2.02E-6	> 1.00E-4
Renal Cancer															
786-0	0.099	0.976	0.947	0.160	0.108	0.082	0.052	97	7	1	-17	-48	3.31E-8	1.13E-6	> 1.00E-4
A498	0.231	1.159	1.102	0.306	0.297	0.400	0.374	94	8	7	18	15	3.25E-8	> 1.00E-4	> 1.00E-4
ACHN	0.266	0.620	0.405	0.178	0.140	0.179	0.171	39	-33	-48	-33	-36	< 1.00E-8	3.48E-8	> 1.00E-4
CAKI-1	0.164	0.431	0.412	0.078	0.056	0.070	0.126	93	-52	-66	-57	-23	1.98E-8	4.36E-8	.
RXF 393	0.272	1.300	1.309	0.815	0.318	0.395	0.310	101	53	4	12	4	1.14E-7	> 1.00E-4	> 1.00E-4
TK-10	0.336	1.033	0.952	0.382	0.262	0.251	0.394	88	7	-22	-25	8	2.95E-8	.	> 1.00E-4
UO-31	0.691	1.214	1.188	0.958	0.284	0.247	0.384	95	51	-59	-64	-44	1.02E-7	2.91E-7	.
Prostate Cancer															
DU-145	0.147	0.542	0.499	0.202	0.137	0.175	0.175	89	14	-7	7	7	3.31E-8	.	> 1.00E-4
Breast Cancer															
MCF7	0.222	1.405	1.410	0.906	0.615	0.395	0.271	100	58	33	15	4	2.08E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.185	0.411	0.360	0.111	0.085	0.098	0.119	78	-40	-54	-47	-36	1.71E-8	4.55E-8	.
HS 578T	0.337	0.617	0.729	0.344	0.280	0.268	0.306	140	2	-17	-21	-9	4.51E-8	1.34E-7	> 1.00E-4
MDA-N	0.125	0.533	0.448	0.201	0.160	0.112	0.096	.	19	9	-10	-24	.	2.83E-6	> 1.00E-4
T-47D	0.257	0.479	0.462	0.338	0.174	0.192	0.263	92	37	-32	-25	3	5.74E-8	.	> 1.00E-4

Table S2. NCI 60-cell line results for **4**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751841 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 1011 (92204)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration												
	Time		Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-9.3	-8.3	-7.3	-6.3	-5.3	-9.3	-8.3	-7.3	-6.3	-5.3	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.687	1.632	1.581	0.653	0.568	0.545	96	92	23	16	15	2.12E-8	> 5.25E-6	> 5.25E-6
HL-60(TB)	0.717	2.144	1.917	1.891	0.908	0.556	0.523	84	82	13	-22	-27	1.54E-8	1.24E-7	> 5.25E-6
K-562	0.257	1.248	1.197	1.037	0.880	0.697	0.424	95	79	63	44	17	2.62E-7	> 5.25E-6	> 5.25E-6
MOLT-4	0.598	1.648	1.770	1.625	1.258	0.860	0.657	112	98	63	25	6	1.14E-7	> 5.25E-6	> 5.25E-6
RPMI-8226	0.685	2.195	2.215	2.174	1.003	0.866	0.740	101	99	21	12	4	2.22E-8	> 5.25E-6	> 5.25E-6
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.013	0.996	0.880	0.276	0.216	0.231	97	80	-22	-39	-35	1.03E-8	3.20E-8	> 5.25E-6
EKVX	0.633	1.534	1.609	1.556	0.671	0.619	0.459	108	102	4	-2	-27	1.79E-8	2.38E-7	> 5.25E-6
HOP-62	0.259	0.851	0.872	0.868	0.290	0.202	0.150	104	103	5	-22	-42	1.83E-8	8.10E-8	> 5.25E-6
HOP-92	1.146	1.965	1.911	1.910	1.852	0.516	0.683	93	93	86	-55	-40	9.47E-8	2.14E-7	.
NCI-H226	0.670	1.492	1.451	1.369	0.958	0.705	0.600	95	85	35	4	-11	2.63E-8	1.01E-6	> 5.25E-6
NCI-H23	0.402	1.242	1.222	1.238	0.790	0.555	0.509	98	99	46	18	13	4.45E-8	> 5.25E-6	> 5.25E-6
NCI-H322M	0.461	0.773	0.785	0.762	0.544	0.465	0.388	104	96	26	1	-16	2.42E-8	6.24E-7	> 5.25E-6
NCI-H460	0.241	1.967	1.892	1.638	0.550	0.500	0.376	96	81	18	15	8	1.62E-8	> 5.25E-6	> 5.25E-6
NCI-H522	0.593	1.451	1.383	1.294	0.919	0.504	0.573	92	82	38	-15	-3	2.78E-8	2.73E-7	> 5.25E-6
Colon Cancer															
COLO 205	0.195	1.194	1.211	1.082	0.432	0.251	0.172	102	89	24	6	-12	2.07E-8	1.09E-6	> 5.25E-6
HCC-2998	0.747	1.776	1.669	1.594	0.525	0.483	0.155	90	82	-30	-35	-79	1.02E-8	2.85E-8	1.13E-6
HCT-116	0.239	1.641	1.589	1.467	0.570	0.417	0.296	96	88	24	13	4	2.03E-8	> 5.25E-6	> 5.25E-6
HCT-15	0.243	1.705	1.562	1.618	1.362	0.824	0.450	90	94	77	40	14	2.76E-7	> 5.25E-6	> 5.25E-6
HT29	0.153	0.816	0.807	0.627	0.175	0.132	0.149	99	71	3	-14	-3	1.08E-8	8.08E-8	> 5.25E-6
KM12	0.247	1.314	1.301	1.162	0.775	0.576	0.396	99	86	49	31	14	5.08E-8	> 5.25E-6	> 5.25E-6
SW-620	0.205	1.161	1.106	0.972	0.448	0.340	0.310	94	80	25	14	11	1.87E-8	> 5.25E-6	> 5.25E-6
CNS Cancer															
SF-268	0.389	1.202	1.177	1.120	0.304	0.179	0.208	97	90	-22	-54	-47	1.20E-8	3.35E-8	.
SF-295	0.751	1.161	1.171	1.065	0.463	0.355	0.301	102	77	-38	-53	-60	8.93E-9	2.43E-8	3.36E-7
SF-539	0.602	1.989	1.936	1.869	1.239	0.520	0.461	96	91	46	-14	-24	4.27E-8	3.09E-7	> 5.25E-6
SNB-19	0.492	1.597	1.498	1.515	0.994	0.716	0.507	91	93	45	20	1	4.20E-8	> 5.25E-6	> 5.25E-6
SNB-75	0.519	1.019	0.957	0.868	0.081	0.038	0.039	88	70	-84	-93	-93	7.05E-9	1.49E-8	3.14E-8
U251	0.273	1.137	1.042	1.017	0.219	0.168	0.192	89	86	-20	-39	-30	1.15E-8	3.41E-8	> 5.25E-6
Melanoma															
LOX IMVI	0.105	0.609	0.596	0.281	0.091	0.067	0.031	97	35	-13	-37	-71	3.01E-9	2.78E-8	1.29E-6
MALME-3M	0.844	1.401	1.328	1.157	0.757	0.654	0.611	87	56	-10	-23	-28	6.52E-9	3.68E-8	> 5.25E-6
M14	0.297	0.951	0.933	0.883	0.435	0.254	0.197	97	90	21	-15	-34	1.98E-8	2.04E-7	> 5.25E-6
MDA-MB-435	0.349	1.178	1.165	1.142	0.562	0.430	0.358	98	96	26	10	1	2.36E-8	> 5.25E-6	> 5.25E-6
SK-MEL-2	0.714	1.526	1.552	1.469	0.585	0.408	0.265	103	93	-18	-43	-63	1.28E-8	3.61E-8	1.19E-6
SK-MEL-28	0.451	1.277	1.270	1.217	0.432	0.178	0.266	99	93	-4	-61	-41	1.45E-8	4.74E-8	.
SK-MEL-5	0.409	2.186	2.156	2.059	1.167	0.318	0.228	98	93	43	-22	-44	3.74E-8	2.38E-7	> 5.25E-6
UACC-257	0.559	0.895	0.824	0.847	0.415	0.320	0.320	79	86	-26	-43	-43	1.09E-8	3.08E-8	> 5.25E-6
UACC-62	0.662	2.016	1.942	1.771	1.217	0.988	0.719	95	82	41	24	4	3.16E-8	> 5.25E-6	> 5.25E-6
Ovarian Cancer															
IGROV1	0.479	0.809	0.858	0.745	0.149	0.216	0.150	115	81	-69	-55	-69	8.41E-9	1.82E-8	3.92E-8
OVCAR-3	0.536	1.382	1.357	1.331	0.425	0.244	0.179	97	94	-21	-54	-67	1.27E-8	3.46E-8	3.87E-7
OVCAR-5	0.488	1.177	1.150	1.127	0.855	0.646	0.590	96	93	53	23	15	6.71E-8	> 5.25E-6	> 5.25E-6
OVCAR-8	0.228	0.678	0.677	0.695	0.395	0.271	0.112	100	104	37	9	-51	3.37E-8	7.52E-7	5.04E-6
NCI/ADR-RES	0.283	0.928	0.917	0.891	0.726	0.462	0.257	98	94	69	28	-9	1.50E-7	2.93E-6	> 5.25E-6
SK-OV-3	0.460	1.016	1.043	0.979	0.446	0.308	0.274	105	93	-3	-33	-40	1.48E-8	4.88E-8	> 5.25E-6
Renal Cancer															
786-0	0.387	1.400	1.362	1.292	0.260	0.171	0.146	96	89	-33	-56	-62	1.10E-8	2.83E-8	2.93E-7
A498	0.736	1.773	1.365	1.179	0.253	0.121	0.184	61	43	-66	-84	-75	2.06E-9	1.30E-8	3.77E-8
ACHN	0.348	1.575	1.558	1.494	0.582	0.392	0.427	99	93	19	4	6	2.01E-8	> 5.25E-6	> 5.25E-6
CAKI-1	0.678	0.962	0.950	1.005	0.226	0.108	0.170	96	115	-67	-84	-75	1.20E-8	2.25E-8	4.25E-8
RXF 393	0.649	1.194	1.166	1.151	0.384	0.298	0.140	95	92	-41	-54	-78	1.09E-8	2.59E-8	2.56E-7
SN12C	0.519	1.891	1.839	1.620	1.235	0.778	0.664	96	80	52	19	11	6.10E-8	> 5.25E-6	> 5.25E-6
TK-10	0.374	1.332	1.259	1.227	0.692	0.306	0.322	92	89	33	-18	-14	2.62E-8	2.32E-7	> 5.25E-6
UO-31	0.569	1.136	1.085	1.033	.	0.171	0.160	91	82	.	-70	-72	1.38E-8	6.29E-8	2.87E-7
Prostate Cancer															
PC-3	0.397	1.634	1.602	1.577	1.286	0.663	0.478	97	95	72	21	7	1.42E-7	> 5.25E-6	> 5.25E-6
DU-145	0.309	1.125	1.145	1.038	0.438	0.341	0.270	102	89	16	4	-13	1.80E-8	9.06E-7	> 5.25E-6
Breast Cancer															
MCF7	0.204	0.894	0.848	0.731	0.317	0.268	0.182	93	76	16	9	-11	1.44E-8	1.50E-6	> 5.25E-6
MDA-MB-231/ATCC	0.449	1.123	1.123	1.032	0.652	0.544	0.450	100	86	30	14	.	2.33E-8	> 5.25E-6	> 5.25E-6
HS 578T	0.514	1.222	1.103	1.114	0.505	0.461	0.403	83	85	-2	-10	-22	1.32E-8	5.01E-8	> 5.25E-6
BT-549	0.792	1.348	1.350	1.245	0.183	0.079	0.061	100	82	-77	-90	-92	8.30E-9	1.72E-8	3.55E-8
T-47D	0.443	1.111	1.068	1.092	0.784	0.568	0.485	94	97	51	19	6	5.65E-8	> 5.25E-6	> 5.25E-6
MDA-MB-468	0.536	1.400	1.379	1.244	0.300	0.233	0.206	98	82	-44	-57	-62	9.42E-9	2.35E-8	1.58E-7

Table S3. NCI 60-cell line results for **5**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751842 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 1010 (92205)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-8.7	-7.7	-6.7	-5.7	-4.7	-8.7	-7.7	-6.7	-5.7	-4.7	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.687	1.546	1.580	0.674	0.612	0.544	89	92	24	20	15	7.51E-8	> 1.80E-5	> 1.80E-5
HL-60(TB)	0.717	2.144	2.104	2.198	1.378	0.542	0.611	97	104	46	-24	-15	1.55E-7	8.12E-7	> 1.80E-5
K-562	0.257	1.248	1.105	1.090	0.913	0.724	0.280	86	84	66	47	2	1.27E-6	> 1.80E-5	> 1.80E-5
MOLT-4	0.598	1.648	1.652	1.659	1.262	0.863	0.542	100	101	63	25	-9	4.01E-7	9.64E-6	> 1.80E-5
RPMI-8226	0.685	2.195	2.182	2.067	1.284	0.927	0.700	99	92	40	16	1	1.14E-7	> 1.80E-5	> 1.80E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.013	1.000	0.967	0.286	0.266	0.179	98	93	-19	-25	-49	4.36E-8	1.22E-7	> 1.80E-5
EKVX	0.633	1.534	1.429	1.428	1.191	0.618	0.582	88	88	62	-2	-8	2.76E-7	1.65E-6	> 1.80E-5
HOP-62	0.259	0.851	0.864	0.878	0.435	0.251	0.221	102	105	30	-3	-15	9.65E-8	1.43E-6	> 1.80E-5
HOP-92	1.146	1.965	1.911	1.803	1.928	0.636	0.919	93	80	95	-45	-20	3.80E-7	8.65E-7	> 1.80E-5
NCI-H226	0.670	1.492	1.380	1.487	1.230	0.754	0.601	86	99	68	10	-10	3.70E-7	5.62E-6	> 1.80E-5
NCI-H23	0.402	1.242	1.235	1.205	0.986	0.642	0.542	99	96	69	29	17	5.38E-7	> 1.80E-5	> 1.80E-5
NCI-H322M	0.461	0.773	0.734	0.772	0.584	0.462	0.423	87	100	39	.	-8	1.20E-7	1.96E-6	> 1.80E-5
NCI-H460	0.241	1.967	1.934	1.883	0.526	0.487	0.212	98	95	17	14	-12	6.75E-8	6.27E-6	> 1.80E-5
NCI-H522	0.593	1.451	1.405	1.439	1.342	0.735	0.371	95	99	87	16	-38	6.06E-7	3.64E-6	> 1.80E-5
Colon Cancer															
COLO 205	0.195	1.194	1.251	1.086	0.465	0.241	0.294	106	89	27	5	10	7.69E-8	> 1.80E-5	> 1.80E-5
HCC-2998	0.747	1.776	1.674	1.639	0.660	0.729	0.114	90	87	-12	-2	-85	4.25E-8	1.37E-7	6.81E-6
HCT-116	0.239	1.641	1.550	1.605	0.776	0.477	0.114	93	97	38	17	-52	1.14E-7	3.16E-6	1.67E-5
HCT-15	0.243	1.705	1.637	1.710	1.533	1.152	0.490	95	100	88	62	17	3.34E-6	> 1.80E-5	> 1.80E-5
HT29	0.153	0.816	0.787	0.764	0.211	0.198	0.123	96	92	9	7	-20	5.75E-8	3.23E-6	> 1.80E-5
KM12	0.247	1.314	1.243	1.280	0.769	0.698	0.291	93	97	49	42	4	1.71E-7	> 1.80E-5	> 1.80E-5
SW-620	0.205	1.161	1.116	1.140	0.554	0.387	0.261	95	98	36	19	6	1.08E-7	> 1.80E-5	> 1.80E-5
CNS Cancer															
SF-268	0.389	1.202	1.147	1.221	0.733	0.237	0.233	93	102	42	-39	-40	1.34E-7	5.95E-7	> 1.80E-5
SF-295	0.751	1.161	1.158	1.213	0.572	0.436	0.269	99	112	-24	-42	-64	5.17E-8	1.20E-7	4.13E-6
SF-539	0.602	1.989	1.950	1.841	1.626	0.701	0.416	97	89	74	7	-31	4.10E-7	2.77E-6	> 1.80E-5
SNB-19	0.492	1.597	1.463	1.504	1.239	0.785	0.524	88	92	68	26	3	4.82E-7	> 1.80E-5	> 1.80E-5
SNB-75	0.519	1.019	0.920	0.977	0.844	0.066	0.095	80	92	65	-87	-82	2.26E-7	4.81E-7	1.02E-6
U251	0.273	1.137	1.125	0.991	0.318	0.218	0.187	99	83	5	-20	-32	4.79E-8	2.88E-7	> 1.80E-5
Melanoma															
LOX IMVI	0.105	0.609	0.564	0.502	0.080	0.086	0.049	91	79	-24	-18	-54	3.43E-8	1.05E-7	1.41E-5
MALME-3M	0.844	1.401	1.241	1.371	1.197	0.641	0.648	71	95	63	-24	-23	2.56E-7	9.56E-7	> 1.80E-5
M14	0.297	0.951	0.919	0.957	0.494	0.389	0.090	95	101	30	14	-70	9.40E-8	2.65E-6	1.04E-5
MDA-MB-435	0.349	1.178	1.113	1.110	0.655	0.540	0.204	92	92	37	23	-42	1.04E-7	4.09E-6	> 1.80E-5
SK-MEL-2	0.714	1.526	1.558	1.626	0.922	0.502	0.398	104	112	26	-30	-44	9.43E-8	5.22E-7	> 1.80E-5
SK-MEL-28	0.451	1.277	1.196	1.301	0.889	0.347	0.285	90	103	53	-23	-37	1.97E-7	8.93E-7	> 1.80E-5
SK-MEL-5	0.409	2.186	2.121	2.128	1.643	0.561	0.293	96	97	69	9	-28	3.75E-7	3.07E-6	> 1.80E-5
UACC-257	0.559	0.895	0.880	0.872	0.514	0.422	0.356	95	93	-8	-25	-36	4.79E-8	1.50E-7	> 1.80E-5
UACC-62	0.662	2.016	1.850	1.925	1.589	1.153	0.771	88	93	68	36	8	6.73E-7	> 1.80E-5	> 1.80E-5
Ovarian Cancer															
IGROV1	0.479	0.809	0.804	0.707	0.160	0.192	0.219	98	69	-67	-60	-54	2.49E-8	5.81E-8	1.36E-7
OVCAR-3	0.536	1.382	1.361	1.387	0.957	0.351	0.364	97	101	50	-35	-32	1.78E-7	7.00E-7	> 1.80E-5
OVCAR-5	0.488	1.177	1.111	1.159	1.054	0.742	0.649	90	97	82	37	23	9.22E-7	> 1.80E-5	> 1.80E-5
OVCAR-8	0.228	0.678	0.691	0.683	0.474	0.309	0.165	103	101	55	18	-28	2.41E-7	4.45E-6	> 1.80E-5
NCI/ADR-RES	0.283	0.928	0.906	0.878	0.855	0.691	0.450	97	92	89	63	26	4.06E-6	> 1.80E-5	> 1.80E-5
SK-OV-3	0.460	1.016	1.033	1.027	0.882	0.427	0.428	103	102	76	-7	-7	3.68E-7	1.47E-6	> 1.80E-5
Renal Cancer															
786-0	0.387	1.400	1.299	1.417	1.026	0.213	0.236	90	102	63	-45	-39	2.38E-7	6.89E-7	> 1.80E-5
A498	0.736	1.773	1.532	1.553	1.360	0.137	0.209	77	79	60	-81	-72	2.12E-7	4.79E-7	1.08E-6
ACHN	0.348	1.575	1.554	1.477	1.200	0.550	0.419	98	92	69	16	6	4.19E-7	> 1.80E-5	> 1.80E-5
CAKI-1	0.678	0.962	0.895	0.805	0.616	0.130	0.195	76	45	-9	-81	-71	1.22E-8	1.21E-7	6.68E-7
RXF 393	0.649	1.194	1.139	1.185	1.142	0.240	0.131	90	98	90	-63	-80	3.30E-7	6.99E-7	1.48E-6
SN12C	0.519	1.891	1.761	1.816	1.589	0.992	0.736	90	95	78	34	16	7.91E-7	> 1.80E-5	> 1.80E-5
TK-10	0.374	1.332	1.284	1.347	1.316	0.513	0.567	95	102	98	14	20	6.78E-7	> 1.80E-5	> 1.80E-5
UO-31	0.569	1.136	1.076	1.094	1.055	0.289	0.388	89	93	86	-49	-32	3.31E-7	7.77E-7	> 1.80E-5
Prostate Cancer															
PC-3	0.397	1.634	1.600	1.461	1.192	0.704	0.538	97	86	64	25	11	4.14E-7	> 1.80E-5	> 1.80E-5
DU-145	0.309	1.125	1.095	1.162	0.794	0.427	0.301	96	104	59	14	-3	2.91E-7	1.27E-5	> 1.80E-5
Breast Cancer															
MCF7	0.204	0.894	0.786	0.865	0.357	0.335	0.127	84	96	22	19	-38	7.53E-8	3.88E-6	> 1.80E-5
MDA-MB-231/ATCC	0.449	1.123	1.055	1.115	0.828	0.583	0.537	90	99	56	20	13	2.67E-7	> 1.80E-5	> 1.80E-5
HS 578T	0.514	1.222	1.256	1.372	1.431	0.709	0.676	105	121	129	27	23	1.08E-6	> 1.80E-5	> 1.80E-5
BT-549	0.792	1.348	1.297	1.371	1.431	0.125	0.106	91	104	115	-84	-87	3.81E-7	6.80E-7	1.21E-6
T-47D	0.443	1.111	1.079	1.042	0.883	0.615	0.412	95	90	66	26	-7	4.45E-7	1.09E-5	> 1.80E-5
MDA-MB-468	0.536	1.400	1.316	1.338	0.457	0.267	0.179	90	93	-15	-50	-67	4.50E-8	1.31E-7	1.77E-6

Table S4. NCI 60-cell line results for **6**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751843 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 1002 (92206)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration												
	Time		Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-8.9	-7.9	-6.9	-5.9	-4.9	-8.9	-7.9	-6.9	-5.9	-4.9	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.660	1.671	1.634	0.872	0.580	0.587	101	98	40	18	18	8.36E-8	> 1.25E-5	> 1.25E-5
HL-60(TB)	0.717	2.333	2.176	2.321	1.867	0.551	0.491	90	99	71	-23	-32	2.09E-7	7.09E-7	> 1.25E-5
K-562	0.257	2.033	1.967	1.710	1.393	1.153	0.768	96	82	64	50	29	1.31E-6	> 1.25E-5	> 1.25E-5
MOLT-4	0.598	1.837	1.854	1.741	1.594	0.912	0.723	101	92	80	25	10	4.45E-7	> 1.25E-5	> 1.25E-5
RPMI-8226	0.685	2.203	2.246	2.215	1.162	0.853	0.753	103	101	31	11	4	6.75E-8	> 1.25E-5	> 1.25E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.345	1.292	1.295	0.529	0.281	0.245	95	95	18	-21	-31	4.77E-8	3.63E-7	> 1.25E-5
EKVX	0.633	1.451	1.542	1.548	1.396	0.602	0.472	111	112	93	-5	-25	3.45E-7	1.11E-6	> 1.25E-5
HOP-62	0.259	0.942	0.930	0.908	0.809	0.223	0.136	98	95	81	-14	-48	2.63E-7	8.91E-7	> 1.25E-5
HOP-92	1.146	1.963	1.889	1.911	1.987	0.616	0.734	91	94	103	-46	-36	2.83E-7	6.12E-7	> 1.25E-5
NCI-H226	0.670	1.472	1.425	1.369	1.169	0.717	0.580	94	87	62	6	-14	2.06E-7	2.51E-6	> 1.25E-5
NCI-H23	0.402	1.272	1.248	1.254	1.131	0.574	0.540	97	98	84	20	16	4.21E-7	> 1.25E-5	> 1.25E-5
NCI-H322M	0.461	0.745	0.787	0.748	0.673	0.451	0.387	115	101	75	-2	-16	2.61E-7	1.17E-6	> 1.25E-5
NCI-H460	0.241	1.964	1.911	1.772	0.558	0.448	0.353	97	89	18	12	6	4.45E-8	> 1.25E-5	> 1.25E-5
NCI-H522	0.593	1.500	1.371	1.324	1.204	0.494	0.390	86	81	67	-17	-34	2.01E-7	7.91E-7	> 1.25E-5
Colon Cancer															
COLO 205	0.195	1.152	1.121	1.060	0.445	0.230	0.163	97	90	26	4	-16	5.32E-8	1.90E-6	> 1.25E-5
HCC-2998	0.747	1.867	1.845	1.754	1.157	0.471	0.229	98	90	37	-37	-69	7.01E-8	3.93E-7	3.15E-6
HCT-116	0.239	1.626	1.579	1.542	0.935	0.421	0.336	97	94	50	13	7	1.26E-7	> 1.25E-5	> 1.25E-5
HCT-15	0.243	1.832	1.728	1.733	1.709	1.284	0.818	93	94	92	65	36	4.22E-6	> 1.25E-5	> 1.25E-5
HT29	0.153	0.976	0.959	0.874	0.345	0.176	0.178	98	88	23	3	3	4.80E-8	> 1.25E-5	> 1.25E-5
KM12	0.247	1.384	1.297	1.203	0.842	0.509	0.395	92	84	52	23	13	1.50E-7	> 1.25E-5	> 1.25E-5
SW-620	0.205	1.102	1.109	1.029	0.582	0.372	0.352	101	92	42	19	16	8.63E-8	> 1.25E-5	> 1.25E-5
CNS Cancer															
SF-268	0.389	1.349	1.266	1.179	1.063	0.255	0.198	91	82	70	-34	-49	1.95E-7	5.86E-7	> 1.25E-5
SF-295	0.751	1.235	1.178	1.166	0.885	0.388	0.298	88	86	28	-48	-60	5.16E-8	2.89E-7	1.72E-6
SF-539	0.602	2.068	2.029	2.025	1.837	0.537	0.559	97	97	84	-11	-7	2.86E-7	9.60E-7	> 1.25E-5
SNB-19	0.492	1.628	1.571	1.488	1.262	0.720	0.698	95	88	68	20	18	2.94E-7	> 1.25E-5	> 1.25E-5
SNB-75	0.519	1.029	0.958	0.845	0.806	0.049	0.045	86	64	56	-91	-91	1.38E-7	3.02E-7	6.61E-7
U251	0.273	1.633	1.542	1.538	0.688	0.218	0.186	93	93	31	-20	-32	6.09E-8	5.00E-7	> 1.25E-5
Melanoma															
LOX IMVI	0.105	0.570	0.530	0.443	0.102	0.060	0.071	91	73	-3	-43	-32	2.49E-8	1.15E-7	> 1.25E-5
MALME-3M	0.844	1.389	1.349	1.211	0.872	0.585	0.518	93	67	5	-31	-39	2.38E-8	1.74E-7	> 1.25E-5
M14	0.297	0.989	1.013	0.970	0.569	0.322	0.231	103	97	39	4	-22	8.15E-8	1.71E-6	> 1.25E-5
MDA-MB-435	0.349	1.173	1.183	1.175	0.597	0.422	0.422	101	100	30	9	9	6.49E-8	> 1.25E-5	> 1.25E-5
SK-MEL-2	0.714	1.610	1.590	1.529	0.717	0.460	0.328	98	91	.	-36	-54	3.53E-8	1.27E-7	7.47E-6
SK-MEL-28	0.451	1.231	1.243	1.170	0.490	0.173	0.201	101	92	5	-62	-55	3.80E-8	1.48E-7	8.36E-7
SK-MEL-5	0.409	2.175	2.160	2.036	1.338	0.340	0.220	99	92	53	-17	-46	1.36E-7	7.12E-7	> 1.25E-5
UACC-257	0.559	0.993	0.976	1.007	0.606	0.336	0.296	96	103	11	-40	-47	4.71E-8	2.03E-7	> 1.25E-5
UACC-62	0.662	2.014	1.950	1.792	1.309	1.007	0.924	95	84	48	26	19	1.09E-7	> 1.25E-5	> 1.25E-5
Ovarian Cancer															
IGROV1	0.479	0.771	0.828	0.733	0.373	0.206	0.150	120	87	-22	-57	-69	2.73E-8	7.84E-8	7.88E-7
OVCAR-3	0.536	1.427	1.472	1.317	1.056	0.246	0.116	105	88	58	-54	-78	1.48E-7	4.12E-7	1.15E-6
OVCAR-5	0.488	1.231	1.175	1.168	1.192	0.651	0.655	93	92	95	22	22	5.14E-7	> 1.25E-5	> 1.25E-5
OVCAR-8	0.228	1.041	1.044	1.078	0.924	0.323	0.220	100	105	86	12	-4	3.79E-7	7.34E-6	> 1.25E-5
NCI/ADR-RES	0.283	0.910	0.916	0.903	0.882	0.635	0.445	101	99	96	56	26	2.00E-6	> 1.25E-5	> 1.25E-5
SK-OV-3	0.460	1.125	1.210	1.327	0.602	0.314	0.246	113	130	21	-32	-47	6.82E-8	3.16E-7	> 1.25E-5
Renal Cancer															
786-0	0.387	1.401	1.421	1.268	1.242	0.172	0.145	102	87	84	-56	-63	2.20E-7	5.00E-7	1.14E-6
A498	0.736	1.442	1.306	1.234	1.221	0.111	0.148	81	71	69	-85	-80	1.65E-7	3.50E-7	7.41E-7
ACHN	0.348	1.644	1.621	1.585	1.466	0.539	0.440	98	95	86	15	7	4.02E-7	> 1.25E-5	> 1.25E-5
CAKI-1	0.678	0.951	1.021	1.033	0.959	0.147	0.098	125	130	103	-78	-86	2.45E-7	4.62E-7	8.72E-7
RXF 393	0.649	1.144	1.107	1.090	1.102	0.170	0.136	93	89	92	-74	-79	2.23E-7	4.47E-7	8.96E-7
SN12C	0.519	1.914	1.880	1.692	1.664	0.846	0.728	98	84	82	23	15	4.40E-7	> 1.25E-5	> 1.25E-5
TK-10	0.374	1.377	1.312	1.260	1.373	0.496	0.357	94	88	100	12	-5	4.62E-7	6.59E-6	> 1.25E-5
UO-31	0.569	1.160	1.114	1.114	1.084	0.312	0.102	92	92	87	-45	-82	2.39E-7	5.70E-7	1.69E-6
Prostate Cancer															
PC-3	0.397	1.602	1.610	1.529	1.239	0.591	0.503	101	94	70	16	9	2.93E-7	> 1.25E-5	> 1.25E-5
DU-145	0.309	1.236	1.160	0.930	0.952	0.357	0.252	92	67	69	5	-18	2.50E-7	2.06E-6	> 1.25E-5
Breast Cancer															
MCF7	0.204	0.817	0.810	0.778	0.358	0.246	0.224	99	94	25	7	3	5.41E-8	> 1.25E-5	> 1.25E-5
MDA-MB-231/ATCC	0.449	1.196	1.160	1.070	0.892	0.572	0.490	95	83	59	16	5	2.06E-7	> 1.25E-5	> 1.25E-5
HS 578T	0.514	1.301	1.250	1.277	1.304	0.562	0.496	93	97	100	6	-4	4.27E-7	5.32E-6	> 1.25E-5
BT-549	0.792	1.354	1.339	1.292	1.091	0.102	0.066	97	89	53	-87	-92	1.32E-7	2.99E-7	6.79E-7
T-47D	0.443	1.197	1.167	1.148	1.095	0.648	0.619	96	94	86	27	23	5.15E-7	> 1.25E-5	> 1.25E-5
MDA-MB-468	0.536	1.431	1.344	1.284	0.661	0.214	0.187	90	84	14	-60	-65	3.80E-8	1.93E-7	9.12E-7

Table S5. NCI 60-cell line results for **7**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751844 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 1003 (92207)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-9.1	-8.1	-7.1	-6.1	-5.1	-9.1	-8.1	-7.1	-6.1	-5.1	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.660	1.622	1.626	0.682	0.614	0.667	97	97	25	20	24	3.64E-8	> 8.00E-6	> 8.00E-6
HL-60(TB)	0.717	2.333	2.269	2.555	1.587	0.617	0.631	96	114	54	-14	-12	9.11E-8	4.98E-7	> 8.00E-6
K-562	0.257	2.033	1.978	2.035	1.808	1.153	1.078	97	100	87	50	46	1.02E-6	> 8.00E-6	> 8.00E-6
MOLT-4	0.598	1.837	1.804	1.786	1.518	0.982	0.830	97	96	74	31	19	2.90E-7	> 8.00E-6	> 8.00E-6
RPMI-8226	0.685	2.203	2.264	2.152	1.336	0.981	0.825	104	97	43	19	9	5.90E-8	> 8.00E-6	> 8.00E-6
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.345	1.285	1.288	0.368	0.383	0.355	94	94	1	3	.	2.40E-8	> 8.00E-6	> 8.00E-6
EKVX	0.633	1.451	1.391	1.417	1.071	0.604	0.576	93	96	54	-5	-9	9.22E-8	6.67E-7	> 8.00E-6
HOP-62	0.259	0.942	0.943	1.008	0.508	0.238	0.238	100	110	36	-8	-8	5.23E-8	5.22E-7	> 8.00E-6
HOP-92	1.146	1.963	1.925	1.848	1.824	0.643	0.717	95	86	83	-44	-37	1.46E-7	3.60E-7	> 8.00E-6
NCI-H226	0.670	1.472	1.397	1.419	1.241	0.770	0.686	91	93	71	12	2	1.84E-7	> 8.00E-6	> 8.00E-6
NCI-H23	0.402	1.272	1.257	1.228	0.970	0.666	0.594	98	95	65	30	22	2.18E-7	> 8.00E-6	> 8.00E-6
NCI-H322M	0.461	0.745	0.710	0.759	0.542	0.473	0.409	88	105	28	4	-11	4.18E-8	1.46E-6	> 8.00E-6
NCI-H460	0.241	1.964	2.031	1.952	0.576	0.579	0.459	104	99	19	20	13	3.31E-8	> 8.00E-6	> 8.00E-6
NCI-H522	0.593	1.500	1.435	1.427	1.204	0.690	0.497	93	92	67	11	-16	1.62E-7	1.99E-6	> 8.00E-6
Colon Cancer															
COLO 205	0.195	1.152	1.151	1.100	0.350	0.201	0.214	100	95	16	1	2	2.96E-8	> 8.00E-6	> 8.00E-6
HCC-2998	0.747	1.867	1.838	1.738	0.832	0.764	0.315	97	88	8	1	-58	2.39E-8	8.47E-7	5.90E-6
HCT-116	0.239	1.626	1.555	1.622	0.754	0.481	0.417	95	100	37	17	13	4.98E-8	> 8.00E-6	> 8.00E-6
HCT-15	0.243	1.832	1.743	1.721	1.609	1.116	0.649	94	93	86	55	26	1.18E-6	> 8.00E-6	> 8.00E-6
HT29	0.153	0.976	0.946	0.913	0.246	0.224	0.191	96	92	11	9	5	2.66E-8	> 8.00E-6	> 8.00E-6
KM12	0.247	1.384	1.342	1.406	0.770	0.726	0.558	96	102	46	42	27	6.78E-8	> 8.00E-6	> 8.00E-6
SW-620	0.205	1.102	1.080	1.101	0.486	0.391	0.310	97	100	31	21	12	4.27E-8	> 8.00E-6	> 8.00E-6
CNS Cancer															
SF-268	0.389	1.349	1.268	1.344	0.860	0.287	0.293	91	99	49	-26	-25	7.66E-8	3.59E-7	> 8.00E-6
SF-295	0.751	1.235	1.139	1.066	0.648	0.467	0.373	80	65	-14	-38	-50	1.24E-8	5.36E-8	7.52E-6
SF-539	0.602	2.068	1.916	1.895	1.637	0.701	0.637	90	88	71	7	2	1.68E-7	> 8.00E-6	> 8.00E-6
SNB-19	0.492	1.628	1.502	1.548	1.241	0.843	0.734	89	93	66	31	21	2.28E-7	> 8.00E-6	> 8.00E-6
SNB-75	0.519	1.029	0.954	1.014	0.783	0.078	0.057	85	97	52	-85	-89	8.24E-8	1.91E-7	4.43E-7
U251	0.273	1.633	1.540	1.443	0.630	0.350	0.299	93	86	26	6	2	3.20E-8	> 8.00E-6	> 8.00E-6
Melanoma															
LOX IMVI	0.105	0.570	0.547	0.480	0.072	0.090	0.066	95	81	-31	-14	-37	1.50E-8	4.20E-8	> 8.00E-6
MALME-3M	0.844	1.389	1.256	1.301	1.034	0.618	0.559	76	84	35	-27	-34	3.94E-8	2.94E-7	> 8.00E-6
M14	0.297	0.989	0.935	1.006	0.546	0.432	0.280	92	102	36	20	-6	4.91E-8	4.69E-6	> 8.00E-6
MDA-MB-435	0.349	1.173	1.129	1.129	0.682	0.558	0.446	95	95	40	25	12	5.31E-8	> 8.00E-6	> 8.00E-6
SK-MEL-2	0.714	1.610	1.582	1.664	0.907	0.629	0.482	97	106	21	-12	-33	3.68E-8	3.51E-7	> 8.00E-6
SK-MEL-28	0.451	1.231	1.201	1.263	0.915	0.351	0.213	96	104	59	-22	-53	1.04E-7	4.27E-7	6.44E-6
SK-MEL-5	0.409	2.175	2.045	2.108	1.550	0.691	0.383	93	96	65	16	-6	1.60E-7	4.12E-6	> 8.00E-6
UACC-257	0.559	0.993	0.972	0.968	0.580	0.500	0.386	95	94	5	-11	-31	2.50E-8	1.63E-7	> 8.00E-6
UACC-62	0.662	2.014	1.919	1.984	1.457	1.068	0.972	93	98	59	30	23	1.62E-7	> 8.00E-6	> 8.00E-6
Ovarian Cancer															
IGROV1	0.479	0.771	0.777	0.672	0.154	0.136	0.172	102	66	-68	-72	-64	1.06E-8	2.49E-8	5.89E-8
OVCAR-3	0.536	1.427	1.353	1.409	1.064	0.365	0.302	92	98	59	-32	-44	1.01E-7	3.57E-7	> 8.00E-6
OVCAR-5	0.488	1.231	1.178	1.120	1.051	0.724	0.630	93	85	76	32	19	3.08E-7	> 8.00E-6	> 8.00E-6
OVCAR-8	0.228	1.041	1.037	0.989	0.770	0.458	0.328	99	94	67	28	12	2.17E-7	> 8.00E-6	> 8.00E-6
NCI/ADR-RES	0.283	0.910	0.901	0.881	0.833	0.684	0.434	99	95	88	64	24	1.79E-6	> 8.00E-6	> 8.00E-6
SK-OV-3	0.460	1.125	1.070	1.030	0.762	0.367	0.317	92	86	45	-20	-31	6.13E-8	3.93E-7	> 8.00E-6
Renal Cancer															
786-0	0.387	1.401	1.320	1.426	1.063	0.200	0.217	92	102	67	-48	-44	1.12E-7	3.04E-7	> 8.00E-6
A498	0.736	1.442	1.299	1.280	1.109	0.126	0.178	80	77	53	-83	-76	8.39E-8	1.96E-7	4.58E-7
ACHN	0.348	1.644	1.514	1.537	1.141	0.566	0.410	90	92	61	17	5	1.43E-7	> 8.00E-6	> 8.00E-6
CAKI-1	0.678	0.951	1.002	1.046	0.862	0.162	0.116	119	135	67	-76	-83	1.06E-7	2.36E-7	5.26E-7
RXF 393	0.649	1.144	1.091	1.099	1.038	0.138	0.228	89	91	79	-79	-65	1.22E-7	2.53E-7	5.25E-7
SN12C	0.519	1.914	1.828	1.842	1.558	1.057	0.767	94	95	74	39	18	3.84E-7	> 8.00E-6	> 8.00E-6
TK-10	0.374	1.377	1.276	1.314	1.313	0.535	0.451	90	94	94	16	8	2.92E-7	> 8.00E-6	> 8.00E-6
UO-31	0.569	1.160	1.025	1.074	0.984	0.294	0.147	77	86	70	-48	-74	1.19E-7	3.13E-7	9.28E-7
Prostate Cancer															
PC-3	0.397	1.602	1.604	1.518	1.128	0.587	0.522	100	93	61	16	10	1.38E-7	> 8.00E-6	> 8.00E-6
DU-145	0.309	1.236	1.174	1.156	0.810	0.415	0.357	93	91	54	11	5	9.94E-8	> 8.00E-6	> 8.00E-6
Breast Cancer															
MCF7	0.204	0.817	0.720	0.835	0.359	0.303	0.237	84	103	25	16	5	3.84E-8	> 8.00E-6	> 8.00E-6
MDA-MB-231/ATCC	0.449	1.196	1.090	1.143	0.811	0.601	0.500	86	93	48	20	7	7.35E-8	> 8.00E-6	> 8.00E-6
HS 578T	0.514	1.301	1.281	1.329	1.367	0.687	0.625	97	104	108	22	14	3.79E-7	> 8.00E-6	> 8.00E-6
BT-549	0.792	1.354	1.326	1.420	1.368	0.156	0.070	95	112	103	-80	-91	1.55E-7	2.91E-7	5.46E-7
T-47D	0.443	1.197	1.139	1.178	1.018	0.697	0.708	92	98	76	34	35	3.31E-7	> 8.00E-6	> 8.00E-6
MDA-MB-468	0.536	1.431	1.327	1.338	0.488	0.299	0.262	88	90	-9	-44	-51	2.02E-8	6.48E-8	5.37E-6

Table S6. NCI 60-cell line results for **8**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751837 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 811 (92196)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-8.8	-7.8	-6.8	-5.8	-4.8	-8.8	-7.8	-6.8	-5.8	-4.8	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.710	1.766	1.734	0.793	0.647	0.536	104	102	33	22	14	8.01E-8	> 1.43E-5	> 1.43E-5
HL-60(TB)	0.717	1.972	2.059	2.071	0.942	0.566	0.489	107	108	18	-21	-32	6.29E-8	4.12E-7	> 1.43E-5
K-562	0.257	1.311	1.312	1.103	0.873	0.716	0.218	100	80	58	44	-15	5.24E-7	7.88E-6	> 1.43E-5
MOLT-4	0.598	1.681	1.699	1.604	1.305	0.894	0.449	102	93	65	27	-25	3.61E-7	4.76E-6	> 1.43E-5
RPMI-8226	0.685	2.244	2.343	2.203	1.400	1.074	0.768	106	97	46	25	5	1.19E-7	> 1.43E-5	> 1.43E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.063	1.096	0.946	0.304	0.285	0.183	105	83	-14	-19	-48	3.15E-8	1.03E-7	> 1.43E-5
EKVX	0.633	1.554	1.614	1.458	1.037	0.590	0.523	107	90	44	-7	-17	1.05E-7	1.05E-6	> 1.43E-5
HOP-62	0.259	0.792	0.763	0.823	0.448	0.292	0.104	95	106	35	6	-60	8.88E-8	1.77E-6	1.01E-5
HOP-92	1.146	2.045	2.004	1.997	1.959	0.582	1.115	95	95	90	-49	-3	2.78E-7	6.35E-7	> 1.43E-5
NCI-H226	0.670	1.448	1.405	1.347	1.079	0.842	0.509	94	87	52	22	-24	1.73E-7	4.29E-6	> 1.43E-5
NCI-H23	0.402	1.274	1.222	1.257	0.800	0.644	0.339	94	98	46	28	-16	1.18E-7	6.20E-6	> 1.43E-5
NCI-H322M	0.461	0.894	0.895	0.884	0.735	0.624	0.394	100	98	63	38	-15	4.69E-7	7.49E-6	> 1.43E-5
NCI-H460	0.241	1.866	1.967	1.232	0.581	0.573	0.132	106	61	21	20	-45	2.69E-8	2.93E-6	> 1.43E-5
NCI-H522	0.593	0.802	0.729	0.637	0.365	0.336	0.150	65	21	-39	-43	-75	3.14E-9	3.21E-8	2.32E-6
Colon Cancer															
COLO 205	0.195	1.210	1.250	1.240	0.534	0.221	0.208	104	103	33	3	1	8.25E-8	> 1.43E-5	> 1.43E-5
HCC-2998	0.747	1.727	1.719	1.483	0.677	0.705	0.114	99	75	-9	-6	-85	2.83E-8	1.11E-7	5.20E-6
HCT-116	0.239	1.640	1.594	1.330	0.725	0.453	0.119	97	78	35	15	-50	6.31E-8	2.44E-6	1.41E-5
HCT-15	0.243	1.573	1.613	1.596	1.481	0.947	0.357	103	102	93	53	9	1.67E-6	> 1.43E-5	> 1.43E-5
HT29	0.153	0.553	0.548	0.452	0.148	0.131	0.098	99	75	-4	-14	-36	2.96E-8	1.29E-7	> 1.43E-5
KM12	0.247	1.278	1.253	1.155	0.715	0.680	0.156	98	88	45	42	-37	1.11E-7	4.86E-6	> 1.43E-5
SW-620	0.205	1.218	1.217	1.017	0.702	0.446	0.187	100	80	49	24	-9	1.33E-7	7.58E-6	> 1.43E-5
CNS Cancer															
SF-268	0.389	1.292	1.277	1.211	0.574	0.352	0.220	98	91	20	-10	-44	5.45E-8	6.83E-7	> 1.43E-5
SF-295	0.751	1.284	1.294	1.295	0.748	0.431	0.211	102	102	.	-43	-72	4.61E-8	1.42E-7	2.55E-6
SF-539	0.602	1.958	1.921	1.844	1.119	0.586	0.238	97	92	38	-3	-61	8.57E-8	1.23E-6	9.39E-6
SNB-19	0.492	1.609	1.473	1.414	0.955	0.839	0.414	88	83	41	31	-16	8.84E-8	6.56E-6	> 1.43E-5
SNB-75	0.519	1.012	0.963	0.900	0.558	0.080	0.035	90	77	8	-85	-93	3.54E-8	1.74E-7	6.04E-7
U251	0.273	1.142	1.101	0.938	0.329	0.210	0.146	95	76	6	-23	-47	3.41E-8	2.36E-7	> 1.43E-5
Melanoma															
LOX IMVI	0.105	0.641	0.556	0.518	0.189	0.089	0.052	84	77	16	-15	-50	3.93E-8	4.59E-7	1.39E-5
MALME-3M	0.844	1.528	1.473	1.302	1.245	0.955	0.627	92	67	59	16	-26	2.28E-7	3.49E-6	> 1.43E-5
M14	0.297	0.994	0.966	0.932	0.608	0.442	0.042	96	91	45	21	-86	1.10E-7	2.24E-6	6.58E-6
MDA-MB-435	0.349	1.201	1.210	1.161	0.797	0.534	0.106	101	95	53	22	-70	1.72E-7	2.47E-6	8.72E-6
SK-MEL-2	0.714	0.999	0.987	0.936	0.573	0.396	0.192	96	78	-20	-45	-73	2.75E-8	8.97E-8	2.21E-6
SK-MEL-28	0.451	1.331	1.332	1.273	1.023	0.777	0.282	100	93	65	37	-38	4.91E-7	4.49E-6	> 1.43E-5
SK-MEL-5	0.409	2.236	2.241	2.072	1.562	0.913	0.049	100	91	63	28	-88	3.34E-7	2.48E-6	6.70E-6
UACC-257	0.559	0.945	0.951	0.943	0.580	0.494	0.323	101	99	5	-12	-42	4.80E-8	2.97E-7	> 1.43E-5
UACC-62	0.662	2.012	1.945	1.801	1.336	1.258	0.455	95	84	50	44	-31	1.42E-7	5.50E-6	> 1.43E-5
Ovarian Cancer															
IGROV1	0.479	0.889	0.997	0.896	0.286	0.202	0.211	126	102	-40	-58	-56	3.31E-8	7.44E-8	5.12E-7
OVCAR-3	0.536	1.356	1.377	1.320	0.894	0.500	0.249	103	96	44	-7	-54	1.08E-7	1.05E-6	1.20E-5
OVCAR-4	0.347	0.599	0.619	0.555	0.418	0.305	0.264	108	83	28	-12	-24	5.70E-8	7.12E-7	> 1.43E-5
OVCAR-5	0.488	1.177	1.157	1.160	0.946	0.733	0.616	97	98	66	36	19	4.88E-7	> 1.43E-5	> 1.43E-5
OVCAR-8	0.228	0.740	0.733	0.729	0.561	0.380	0.142	99	98	65	30	-38	3.82E-7	3.94E-6	> 1.43E-5
NCI/ADR-RES	0.283	0.940	0.953	0.937	0.875	0.601	0.288	102	99	90	48	1	1.31E-6	> 1.43E-5	> 1.43E-5
SK-OV-3	0.460	1.035	1.039	1.030	0.790	0.518	0.338	101	99	57	10	-27	2.05E-7	2.69E-6	> 1.43E-5
Renal Cancer															
786-0	0.387	1.439	1.454	1.372	0.980	0.176	0.194	101	94	56	-55	-50	1.63E-7	4.60E-7	1.43E-5
A498	0.736	1.432	1.397	1.212	0.897	0.129	0.218	95	68	23	-83	-70	3.63E-8	2.36E-7	7.03E-7
ACHN	0.348	1.550	1.556	1.501	1.191	0.494	0.366	100	96	70	12	1	3.18E-7	> 1.43E-5	> 1.43E-5
CAKI-1	0.678	1.038	1.046	1.088	0.905	0.163	0.197	102	114	63	-76	-71	1.78E-7	4.06E-7	9.30E-7
RXF 393	0.649	1.230	1.198	1.190	0.902	0.185	0.062	94	93	44	-71	-90	1.06E-7	3.42E-7	9.30E-7
SN12C	0.519	1.912	1.895	1.716	1.403	1.064	0.646	99	86	63	39	9	5.10E-7	> 1.43E-5	> 1.43E-5
TK-10	0.374	0.529	0.520	0.494	0.245	0.141	0.188	94	77	-34	-62	-50	2.51E-8	7.03E-8	.
UO-31	0.569	1.188	1.159	1.148	1.094	0.262	0.303	95	94	85	-54	-47	2.55E-7	5.84E-7	.
Prostate Cancer															
PC-3	0.397	1.621	1.693	1.670	1.310	0.869	0.503	106	104	75	39	9	6.87E-7	> 1.43E-5	> 1.43E-5
DU-145	0.309	1.123	1.152	1.009	0.856	0.443	0.199	104	86	67	16	-36	3.13E-7	2.96E-6	> 1.43E-5
Breast Cancer															
MCF7	0.204	1.049	1.031	0.916	0.590	0.476	0.161	98	84	46	32	-21	1.10E-7	5.71E-6	> 1.43E-5
MDA-MB-231/ATCC	0.449	1.138	1.125	1.022	0.733	0.613	0.412	98	83	41	24	-8	8.80E-8	7.85E-6	> 1.43E-5
HS 578T	0.514	1.108	1.107	1.124	0.926	0.571	0.388	100	103	69	10	-25	3.01E-7	2.72E-6	> 1.43E-5
BT-549	0.792	1.372	1.349	1.322	1.020	0.213	0.065	96	91	39	-73	-92	8.90E-8	3.20E-7	8.90E-7
T-47D	0.443	0.940	0.922	0.948	0.818	0.703	0.338	96	102	76	52	-24	1.54E-6	6.98E-6	> 1.43E-5
MDA-MB-468	0.536	1.361	1.314	1.124	0.588	0.352	0.130	94	71	6	-34	-76	3.04E-8	2.04E-7	3.42E-6

Table S7. NCI 60-cell line results for **9**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 666654 / 1	Experiment ID : 9312SR87	Test Type : 08	Units : Molar
Report Date : April 12, 2010	Test Date : December 14, 1993	QNS :	MC :
COMI : PC# 447	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration												
	Time		Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.347	0.902	0.944	0.925	0.551	0.552	0.507	107	104	37	37	29	6.34E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.515	1.549	1.620	1.388	0.563	0.398	0.340	107	84	5	-23	-34	2.70E-7	1.48E-6	> 1.00E-4
K-562	0.161	0.871	0.845	0.726	0.492	0.499	0.294	96	80	47	48	19	7.92E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.428	1.526	1.513	1.521	1.052	0.959	0.576	99	99	57	48	13	6.38E-6	> 1.00E-4	> 1.00E-4
RPMI-8226	0.300	0.547	0.533	0.463	0.336	0.290	0.210	94	66	15	-3	-30	2.03E-7	6.40E-6	> 1.00E-4
SR	0.396	1.452	1.549	1.394	1.015	0.859	0.365	109	95	59	44	-8	3.85E-6	7.06E-5	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.433	1.745	1.766	1.755	1.563	0.899	0.419	102	101	86	36	-3	5.18E-6	8.20E-5	> 1.00E-4
EKVX	0.823	1.964	1.943	1.939	1.842	1.281	0.823	98	98	89	40	.	6.29E-6	9.97E-5	> 1.00E-4
HOP-62	0.281	0.870	0.912	0.863	0.650	0.433	0.171	107	99	63	26	-39	2.20E-6	2.50E-5	> 1.00E-4
NCI-H226	1.117	1.590	1.538	1.519	1.546	1.028	0.386	89	85	91	-8	-65	2.59E-6	8.30E-6	5.39E-5
NCI-H23	0.825	2.225	2.163	2.181	1.502	1.323	0.854	96	97	48	36	2	9.24E-7	> 1.00E-4	> 1.00E-4
NCI-H322M	0.516	1.399	1.452	1.541	1.314	0.984	0.637	106	116	90	53	14	1.19E-5	> 1.00E-4	> 1.00E-4
NCI-H460	0.209	1.818	1.773	1.587	0.757	0.501	0.235	97	86	34	18	2	4.91E-7	> 1.00E-4	> 1.00E-4
NCI-H522	0.340	0.891	0.875	0.642	0.267	0.459	0.171	97	55	-22	22	-50	1.15E-7	.	> 1.00E-4
Colon Cancer															
COLO 205	0.191	1.745	1.688	1.760	0.774	0.409	0.410	96	101	38	14	14	6.36E-7	> 1.00E-4	> 1.00E-4
HCC-2998	0.243	0.472	0.433	0.424	0.274	0.301	0.142	83	79	13	25	-42	2.77E-7	2.38E-5	> 1.00E-4
HCT-116	0.170	1.451	1.375	1.222	0.339	0.525	0.271	94	82	13	28	8	2.92E-7	> 1.00E-4	> 1.00E-4
HCT-15	0.308	1.306	1.385	1.387	1.358	1.257	0.529	108	108	105	95	22	4.15E-5	> 1.00E-4	> 1.00E-4
HT29	0.184	1.421	1.373	1.382	0.721	0.335	0.273	96	97	43	12	7	7.53E-7	> 1.00E-4	> 1.00E-4
KM12	0.395	1.660	1.676	1.593	1.048	1.060	0.620	101	95	52	53	18	1.19E-5	> 1.00E-4	> 1.00E-4
SW-620	0.165	0.659	0.670	0.654	0.394	0.473	0.329	102	99	46	62	33	.	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.514	1.095	1.114	1.135	1.116	0.569	0.398	103	107	104	9	-23	3.71E-6	1.97E-5	> 1.00E-4
SF-295	0.325	1.078	1.144	1.237	0.990	0.734	0.268	109	121	88	54	-18	1.15E-5	5.68E-5	> 1.00E-4
SF-539	0.635	1.496	1.508	1.630	1.419	0.668	0.368	101	116	91	4	-42	2.96E-6	1.21E-5	> 1.00E-4
SNB-19	0.746	1.915	1.969	1.874	1.581	1.091	0.575	105	97	71	30	-23	3.24E-6	3.65E-5	> 1.00E-4
SNB-75	0.417	1.394	1.349	1.278	1.079	0.394	0.174	95	88	.	-6	-58	6.53E-7	7.62E-6	6.97E-5
U251	0.677	2.236	2.245	2.072	1.280	0.901	0.565	101	89	39	14	-17	5.98E-7	2.92E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.212	0.776	0.739	0.702	0.227	0.240	0.217	94	87	3	5	1	2.75E-7	> 1.00E-4	> 1.00E-4
MALME-3M	0.375	0.783	0.823	0.823	0.743	0.566	0.356	110	110	90	47	-5	8.43E-6	7.94E-5	> 1.00E-4
M14	0.176	0.662	0.725	0.602	0.556	0.328	0.146	113	88	78	31	-17	3.99E-6	4.48E-5	> 1.00E-4
SK-MEL-2	0.452	1.139	1.074	1.109	0.679	0.546	0.226	91	96	33	14	-50	5.36E-7	1.64E-5	9.96E-5
SK-MEL-28	0.622	1.919	1.870	1.862	1.431	1.199	0.465	96	96	62	44	-25	4.90E-6	4.34E-5	> 1.00E-4
SK-MEL-5	0.315	1.498	1.350	1.076	0.713	0.434	0.203	87	64	34	10	-36	2.93E-7	1.66E-5	> 1.00E-4
UACC-257	0.462	1.731	1.710	1.738	0.954	0.918	0.577	98	101	39	36	9	6.59E-7	> 1.00E-4	> 1.00E-4
UACC-62	0.353	1.470	1.470	1.505	0.788	0.716	0.164	100	103	39	32	-54	6.71E-7	2.38E-5	9.06E-5
Ovarian Cancer															
IGROV1	0.323	1.474	1.418	1.413	1.116	0.297	0.164	95	95	69	-8	-49	1.76E-6	7.89E-6	> 1.00E-4
OVCAR-4	0.186	0.533	0.516	0.542	0.463	0.360	0.209	95	103	80	50	7	1.01E-5	> 1.00E-4	> 1.00E-4
OVCAR-5	0.703	1.285	1.323	1.294	1.221	0.920	0.613	107	102	89	37	-13	5.67E-6	5.55E-5	> 1.00E-4
OVCAR-8	0.305	1.623	1.634	1.635	1.570	0.957	0.362	101	101	96	49	4	9.75E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.359	0.932	1.004	0.974	0.960	1.018	0.809	113	107	105	115	79	> 1.00E-4	> 1.00E-4	> 1.00E-4
SK-OV-3	0.256	0.686	0.660	0.674	0.711	0.419	0.150	94	97	106	38	-42	6.61E-6	2.99E-5	> 1.00E-4
Renal Cancer															
786-0	0.207	1.159	1.192	1.189	1.131	0.581	0.140	104	103	97	39	-32	6.51E-6	3.53E-5	> 1.00E-4
ACHN	0.432	1.770	1.768	1.805	1.681	1.110	0.437	100	103	93	51	.	1.03E-5	> 1.00E-4	> 1.00E-4
CAKI-1	0.286	1.242	1.202	1.205	1.279	0.875	0.062	96	96	104	62	-78	1.21E-5	2.75E-5	6.26E-5
RXF 393	1.144	1.485	1.456	1.532	1.549	0.867	0.212	91	114	119	-24	-82	3.03E-6	6.77E-6	2.82E-5
SN12C	0.320	1.134	1.141	1.123	0.987	0.630	0.438	101	99	82	38	14	5.35E-6	> 1.00E-4	> 1.00E-4
TK-10	0.891	1.688	1.748	1.747	1.813	1.232	0.417	108	107	116	43	-53	7.95E-6	2.79E-5	9.26E-5
UO-31	1.124	2.188	2.035	2.055	2.202	2.105	0.233	86	87	101	92	-79	1.76E-5	3.45E-5	6.75E-5
Prostate Cancer															
PC-3	0.575	1.493	1.523	1.630	1.069	0.843	0.510	103	115	54	29	-11	1.43E-6	5.26E-5	> 1.00E-4
DU-145	0.495	1.589	1.673	1.690	1.611	1.239	0.523	108	109	102	68	3	1.88E-5	> 1.00E-4	> 1.00E-4
Breast Cancer															
MCF7	0.335	1.008	0.967	0.913	0.663	0.418	0.211	94	86	49	12	-37	9.27E-7	1.77E-5	> 1.00E-4
MDA-MB-231/ATCC	0.360	0.970	1.001	0.982	0.825	0.423	0.196	105	102	76	10	-46	2.50E-6	1.52E-5	> 1.00E-4
HS 578T	0.577	1.568	1.452	1.493	1.438	0.846	0.551	88	93	87	27	-5	4.15E-6	7.21E-5	> 1.00E-4
MDA-N	0.385	2.058	2.073	2.041	1.859	1.209	0.539	101	99	88	49	9	9.58E-6	> 1.00E-4	> 1.00E-4
BT-549	0.840	1.412	1.403	1.422	1.514	0.901	0.269	98	102	118	11	-68	4.29E-6	1.37E-5	5.90E-5
T-47D	0.534	1.185	1.122	1.255	1.359	1.193	0.622	90	111	127	101	13	3.83E-5	> 1.00E-4	> 1.00E-4

Table S8. NCI 60-cell line results for **11**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751840 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 889 (92203)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration												
	Time		Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-8.8	-7.8	-6.8	-5.8	-4.8	-8.8	-7.8	-6.8	-5.8	-4.8	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.583	1.524	1.547	1.156	0.845	0.647	95	97	65	40	24	6.73E-7	> 1.65E-5	> 1.65E-5
HL-60(TB)	0.717	2.326	2.129	2.097	1.136	0.623	0.562	88	86	26	-13	-22	6.55E-8	7.63E-7	> 1.65E-5
K-562	0.257	1.337	1.249	1.223	0.960	0.782	0.327	92	89	65	49	6	1.35E-6	> 1.65E-5	> 1.65E-5
MOLT-4	0.598	1.723	1.706	1.545	1.404	1.116	0.535	98	84	72	46	-11	1.15E-6	1.07E-5	> 1.65E-5
RPMI-8226	0.685	2.244	2.212	2.156	1.406	1.254	0.680	98	94	46	36	-1	1.38E-7	1.57E-5	> 1.65E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.074	1.057	1.072	0.928	0.446	0.270	98	100	80	13	-24	4.59E-7	3.71E-6	> 1.65E-5
EKVX	0.633	1.567	1.506	1.516	1.400	0.895	0.618	93	95	82	28	-2	6.48E-7	1.38E-5	> 1.65E-5
HOP-62	0.259	0.766	0.840	0.767	0.654	0.442	0.255	115	100	78	36	-2	7.69E-7	1.50E-5	> 1.65E-5
HOP-92	1.146	1.967	1.928	1.797	1.834	1.481	1.010	95	79	84	41	-12	1.01E-6	9.81E-6	> 1.65E-5
NCI-H226	0.670	1.461	1.384	1.496	1.452	1.129	0.819	90	104	99	58	19	2.64E-6	> 1.65E-5	> 1.65E-5
NCI-H23	0.402	1.268	1.256	1.202	0.879	0.788	0.592	99	92	55	45	22	4.94E-7	> 1.65E-5	> 1.65E-5
NCI-H322M	0.461	0.875	0.846	0.873	0.844	0.689	0.493	93	100	93	55	8	2.12E-6	> 1.65E-5	> 1.65E-5
NCI-H460	0.241	2.027	2.037	2.149	1.176	0.568	0.396	101	107	52	18	9	1.93E-7	> 1.65E-5	> 1.65E-5
NCI-H522	0.593	1.325	1.236	1.103	0.712	0.609	0.579	88	70	16	2	-2	3.85E-8	4.89E-6	> 1.65E-5
Colon Cancer															
COLO 205	0.195	1.172	1.200	1.124	0.632	0.134	0.239	103	95	45	-32	5	1.29E-7		> 1.65E-5
HCC-2998	0.747	1.716	1.782	1.563	0.814	0.705	0.458	107	84	7	-6	-39	4.57E-8	5.84E-7	> 1.65E-5
HCT-116	0.239	1.618	1.567	1.612	0.623	0.572	0.358	96	100	28	24	9	8.10E-8	> 1.65E-5	> 1.65E-5
HCT-15	0.243	1.683	1.545	1.524	1.477	1.544	0.929	90	89	86	90	48	1.45E-5	> 1.65E-5	> 1.65E-5
HT29	0.153	0.626	0.622	0.607	0.361	0.161	0.165	99	96	44	2	3	1.27E-7	> 1.65E-5	> 1.65E-5
KM12	0.247	1.273	1.225	1.253	0.683	0.704	0.472	95	98	43	45	22	1.21E-7	> 1.65E-5	> 1.65E-5
SW-620	0.205	1.204	1.093	1.129	0.561	0.533	0.439	89	93	36	33	23	9.21E-8	> 1.65E-5	> 1.65E-5
CNS Cancer															
SF-268	0.389	1.189	1.118	1.183	0.988	0.537	0.342	91	99	75	19	-12	4.56E-7	6.64E-6	> 1.65E-5
SF-295	0.751	1.251	1.166	1.174	0.913	0.884	0.489	83	85	32	27	-35	7.60E-8	4.45E-6	> 1.65E-5
SF-539	0.602	1.924	1.931	1.871	1.703	0.961	0.731	101	96	83	27	10	6.46E-7	> 1.65E-5	> 1.65E-5
SNB-19	0.492	1.645	1.510	1.543	1.459	0.954	0.809	88	91	84	40	28	9.78E-7	> 1.65E-5	> 1.65E-5
SNB-75	0.519	1.003	0.915	0.979	1.022	0.557	0.160	82	95	104	8	-69	5.99E-7	2.08E-6	9.29E-6
U251	0.273	1.184	1.153	0.939	0.483	0.332	0.270	97	73	23	6	-1	4.78E-8	1.18E-5	> 1.65E-5
Melanoma															
LOX IMVI	0.105	0.588	0.599	0.518	0.346	0.157	0.088	102	86	50	11	-16	1.63E-7	4.14E-6	> 1.65E-5
MALME-3M	0.844	1.496	1.379	1.492	1.389	1.121	0.835	82	99	84	43	-1	1.09E-6	1.56E-5	> 1.65E-5
M14	0.297	1.004	0.937	0.968	0.977	0.681	0.340	90	95	96	54	6	2.02E-6	> 1.65E-5	> 1.65E-5
MDA-MB-435	0.349	1.179	1.118	1.104	1.084	0.723	0.394	93	91	89	45	5	1.27E-6	> 1.65E-5	> 1.65E-5
SK-MEL-2	0.714	1.285	1.292	1.294	0.948	0.637	0.347	101	102	41	-11	-51	1.17E-7	1.02E-6	1.52E-5
SK-MEL-28	0.451	1.302	1.242	1.320	1.153	0.937	0.424	93	102	82	57	-6	2.14E-6	1.33E-5	> 1.65E-5
SK-MEL-5	0.409	2.204	2.118	2.148	1.086	0.524	0.360	95	97	38	6	-12	1.02E-7	3.65E-6	> 1.65E-5
UACC-257	0.559	0.953	0.912	0.929	0.888	0.579	0.376	90	94	83	5	-33	4.40E-7	2.25E-6	> 1.65E-5
UACC-62	0.662	1.886	1.768	1.853	1.659	1.267	0.809	90	97	81	49	12	1.58E-6	> 1.65E-5	> 1.65E-5
Ovarian Cancer															
IGROV1	0.479	0.901	0.801	0.824	0.693	0.267	0.255	76	82	51	-44	-47	1.68E-7	5.64E-7	> 1.65E-5
OVCAR-3	0.536	1.288	1.224	1.254	1.179	0.656	0.371	91	95	86	16	-31	5.34E-7	3.61E-6	> 1.65E-5
OVCAR-4	0.347	0.563	0.522	0.549	0.475	0.341	0.301	81	94	59	-2	-13	2.35E-7	1.54E-6	> 1.65E-5
OVCAR-5	0.488	1.171	1.111	1.099	1.090	0.820	0.698	91	89	88	49	31	1.52E-6	> 1.65E-5	> 1.65E-5
OVCAR-8	0.228	0.781	0.752	0.700	0.701	0.502	0.253	95	85	86	50	4	1.60E-6	> 1.65E-5	> 1.65E-5
NCI/ADR-RES	0.283	0.933	0.968	0.916	0.912	0.940	0.740	105	97	97	101	70	> 1.65E-5	> 1.65E-5	> 1.65E-5
SK-OV-3	0.460	1.080	1.048	1.024	1.043	0.860	0.419	95	91	94	64	-9	2.60E-6	1.25E-5	> 1.65E-5
Renal Cancer															
786-0	0.387	1.402	1.373	1.430	1.390	1.006	0.203	97	103	99	61	-48	2.08E-6	6.01E-6	> 1.65E-5
A498	0.736	1.636	1.426	1.467	1.383	0.922	0.177	77	81	72	21	-76	4.41E-7	2.70E-6	8.89E-6
ACHN	0.348	1.536	1.436	1.416	1.437	1.217	0.465	92	90	92	73	10	3.83E-6	> 1.65E-5	> 1.65E-5
CAKI-1	0.678	0.970	0.942	0.911	0.989	0.965	0.154	90	80	106	98	-77	3.11E-6	5.99E-6	1.15E-5
RXF 393	0.649	1.251	1.162	1.216	1.206	0.897	0.235	85	94	92	41	-64	1.11E-6	4.07E-6	1.22E-5
SN12C	0.519	1.800	1.706	1.727	1.637	1.283	0.800	93	94	87	60	22	2.97E-6	> 1.65E-5	> 1.65E-5
TK-10	0.374	0.854	0.783	0.755	0.680	0.383	0.264	85	79	64	2	-29	2.74E-7	1.88E-6	> 1.65E-5
UO-31	0.569	1.186	1.080	1.150	1.143	1.182	0.200	83	94	93	99	-65	3.29E-6	6.64E-6	1.34E-5
Prostate Cancer															
PC-3	0.397	1.562	1.530	1.489	1.302	0.962	0.606	97	94	78	48	18	1.47E-6	> 1.65E-5	> 1.65E-5
DU-145	0.309	1.071	1.036	1.073	1.052	0.886	0.331	95	100	98	76	3	3.72E-6	> 1.65E-5	> 1.65E-5
Breast Cancer															
MCF7	0.204	0.931	0.909	0.917	0.644	0.523	0.257	97	98	60	44	7	7.03E-7	> 1.65E-5	> 1.65E-5
MDA-MB-231/ATCC	0.449	1.112	1.041	1.066	0.968	0.680	0.494	89	93	78	35	7	7.39E-7	> 1.65E-5	> 1.65E-5
HS 578T	0.514	1.153	1.124	1.159	1.146	0.756	0.530	95	101	99	38	3	1.04E-6	> 1.65E-5	> 1.65E-5
BT-549	0.792	1.362	1.334	1.445	1.609	1.005	0.405	95	115	143	37	-49	1.25E-6	4.47E-6	> 1.65E-5
T-47D	0.443	0.919	0.870	0.857	0.750	0.741	0.466	90	87	65	63	5	2.73E-6	> 1.65E-5	> 1.65E-5
MDA-MB-468	0.536	1.371	1.282	1.178	0.362	0.530	0.272	89	77	-32	-1	-49	2.91E-8	8.33E-8	> 1.65E-5

Table S9. NCI 60-cell line results for **12**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751838 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 812 (92197)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-8.7	-7.7	-6.7	-5.7	-4.7	-8.7	-7.7	-6.7	-5.7	-4.7	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.710	1.620	1.571	1.591	1.743	1.121	93	90	91	102	57	> 2.23E-5	> 2.23E-5	> 2.23E-5
HL-60(TB)	0.717	1.972	2.008	2.016	1.959	2.086	1.020	103	103	99	109	24	1.11E-5	> 2.23E-5	> 2.23E-5
K-562	0.257	1.311	1.279	1.349	1.305	1.187	0.952	97	104	99	88	66	> 2.23E-5	> 2.23E-5	> 2.23E-5
MOLT-4	0.598	1.681	1.612	1.689	1.695	1.723	1.120	94	101	101	104	48	2.07E-5	> 2.23E-5	> 2.23E-5
RPMI-8226	0.685	2.244	2.262	2.215	2.210	2.259	1.562	101	98	98	101	56	> 2.23E-5	> 2.23E-5	> 2.23E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.063	1.069	1.058	1.071	1.035	0.652	101	99	101	96	42	1.59E-5	> 2.23E-5	> 2.23E-5
EKVX	0.633	1.554	1.573	1.432	1.463	1.477	1.392	102	87	90	92	82	> 2.23E-5	> 2.23E-5	> 2.23E-5
HOP-62	0.259	0.792	0.773	0.768	0.768	0.746	0.629	96	96	95	91	69	> 2.23E-5	> 2.23E-5	> 2.23E-5
HOP-92	1.146	2.045	1.941	1.875	1.892	1.901	1.954	88	81	83	84	90	> 2.23E-5	> 2.23E-5	> 2.23E-5
NCI-H226	0.670	1.448	1.364	1.428	1.338	1.371	1.355	89	97	86	90	88	> 2.23E-5	> 2.23E-5	> 2.23E-5
NCI-H23	0.402	1.274	1.227	1.218	1.197	1.191	0.792	95	94	91	90	45	1.71E-5	> 2.23E-5	> 2.23E-5
NCI-H322M	0.461	0.894	0.847	0.892	0.892	0.940	0.843	89	99	100	111	88	> 2.23E-5	> 2.23E-5	> 2.23E-5
NCI-H460	0.241	1.866	1.911	1.891	1.912	1.782	0.750	103	102	103	95	31	1.13E-5	> 2.23E-5	> 2.23E-5
NCI-H522	0.593	0.802	0.738	0.752	0.751	0.751	0.371	69	76	75	75	-38	3.75E-6	1.04E-5	> 2.23E-5
Colon Cancer															
COLO 205	0.195	1.210	1.211	1.229	1.150	1.062	0.522	100	102	94	85	32	1.03E-5	> 2.23E-5	> 2.23E-5
HCC-2998	0.747	1.727	1.758	1.688	1.678	1.706	0.880	103	96	95	98	14	8.24E-6	> 2.23E-5	> 2.23E-5
HCT-116	0.239	1.640	1.542	1.598	1.585	1.658	0.627	93	97	96	101	28	1.11E-5	> 2.23E-5	> 2.23E-5
HCT-15	0.243	1.573	1.635	1.422	1.494	1.476	1.549	105	89	94	93	98	> 2.23E-5	> 2.23E-5	> 2.23E-5
HT29	0.153	0.553	0.532	0.561	0.550	0.513	0.300	95	102	99	90	37	1.26E-5	> 2.23E-5	> 2.23E-5
KM12	0.247	1.278	1.203	1.242	1.194	1.255	0.834	93	97	92	98	57	> 2.23E-5	> 2.23E-5	> 2.23E-5
SW-620	0.205	1.218	1.103	1.155	1.055	1.107	0.627	89	94	84	89	42	1.49E-5	> 2.23E-5	> 2.23E-5
CNS Cancer															
SF-268	0.389	1.292	1.222	1.235	1.193	1.180	0.987	92	94	89	88	66	> 2.23E-5	> 2.23E-5	> 2.23E-5
SF-295	0.751	1.284	1.236	1.230	1.272	1.199	0.726	91	90	98	84	-3	5.46E-6	2.04E-5	> 2.23E-5
SF-539	0.602	1.958	1.829	1.829	1.787	1.894	1.869	90	90	87	95	93	> 2.23E-5	> 2.23E-5	> 2.23E-5
SNB-19	0.492	1.609	1.544	1.594	1.487	1.583	1.397	94	99	89	98	81	> 2.23E-5	> 2.23E-5	> 2.23E-5
SNB-75	0.519	1.012	0.912	0.942	0.910	0.937	1.033	80	86	79	85	104	> 2.23E-5	> 2.23E-5	> 2.23E-5
U251	0.273	1.142	1.125	1.103	1.124	1.088	0.525	98	95	98	94	29	1.06E-5	> 2.23E-5	> 2.23E-5
Melanoma															
LOX IMVI	0.105	0.641	0.542	0.568	0.567	0.607	0.081	81	86	86	94	-23	5.26E-6	1.41E-5	> 2.23E-5
MALME-3M	0.844	1.528	1.315	1.431	1.378	1.393	1.377	69	86	78	80	78	> 2.23E-5	> 2.23E-5	> 2.23E-5
M14	0.297	0.994	0.927	0.954	0.937	0.949	0.915	90	94	92	94	89	> 2.23E-5	> 2.23E-5	> 2.23E-5
MDA-MB-435	0.349	1.201	1.136	1.161	1.144	1.219	0.957	92	95	93	102	71	> 2.23E-5	> 2.23E-5	> 2.23E-5
SK-MEL-2	0.714	0.999	0.992	1.010	0.962	1.014	0.692	97	104	87	105	-3	7.20E-6	2.09E-5	> 2.23E-5
SK-MEL-28	0.451	1.331	1.300	1.335	1.301	1.371	1.168	97	100	97	105	81	> 2.23E-5	> 2.23E-5	> 2.23E-5
SK-MEL-5	0.409	2.236	2.047	2.200	2.127	2.058	0.875	90	98	94	90	25	9.33E-6	> 2.23E-5	> 2.23E-5
UACC-257	0.559	0.945	0.946	0.908	0.894	0.948	0.791	100	90	87	101	60	> 2.23E-5	> 2.23E-5	> 2.23E-5
UACC-62	0.662	2.012	1.887	1.936	1.798	1.849	1.547	91	94	84	88	66	> 2.23E-5	> 2.23E-5	> 2.23E-5
Ovarian Cancer															
IGROV1	0.479	0.889	0.822	0.877	0.794	0.780	0.671	84	97	77	73	47	1.69E-5	> 2.23E-5	> 2.23E-5
OVCAR-3	0.536	1.356	1.296	1.322	1.296	1.275	1.299	93	96	93	90	93	> 2.23E-5	> 2.23E-5	> 2.23E-5
OVCAR-4	0.347	0.599	0.584	0.602	0.587	0.578	0.514	94	101	95	92	66	> 2.23E-5	> 2.23E-5	> 2.23E-5
OVCAR-5	0.488	1.177	1.129	1.079	1.026	1.134	1.058	93	86	78	94	83	> 2.23E-5	> 2.23E-5	> 2.23E-5
OVCAR-8	0.228	0.740	0.764	0.708	0.720	0.731	0.685	105	94	96	98	89	> 2.23E-5	> 2.23E-5	> 2.23E-5
NCI/ADR-RES	0.283	0.940	0.936	0.923	0.920	0.869	0.928	99	97	97	89	98	> 2.23E-5	> 2.23E-5	> 2.23E-5
SK-OV-3	0.460	1.035	0.987	0.982	0.989	0.951	1.090	92	91	92	85	110	> 2.23E-5	> 2.23E-5	> 2.23E-5
Renal Cancer															
786-0	0.387	1.439	1.398	1.435	1.431	1.456	1.430	96	100	99	102	99	> 2.23E-5	> 2.23E-5	> 2.23E-5
A498	0.736	1.432	1.279	1.320	1.255	1.277	1.247	78	84	75	78	73	> 2.23E-5	> 2.23E-5	> 2.23E-5
ACHN	0.348	1.550	1.504	1.480	1.419	1.468	1.182	96	94	89	93	69	> 2.23E-5	> 2.23E-5	> 2.23E-5
CAKI-1	0.678	1.038	1.007	0.988	0.939	1.077	1.034	91	86	73	111	99	> 2.23E-5	> 2.23E-5	> 2.23E-5
RXF 393	0.649	1.230	1.155	1.176	1.161	1.183	1.182	87	91	88	92	92	> 2.23E-5	> 2.23E-5	> 2.23E-5
SN12C	0.519	1.912	1.792	1.815	1.752	1.756	1.703	91	93	88	89	85	> 2.23E-5	> 2.23E-5	> 2.23E-5
TK-10	0.374	0.529	0.515	0.514	0.522	0.511	0.377	91	90	95	88	2	6.20E-6	> 2.23E-5	> 2.23E-5
UO-31	0.569	1.188	1.110	1.108	1.095	1.049	1.117	87	87	85	78	89	> 2.23E-5	> 2.23E-5	> 2.23E-5
Prostate Cancer															
PC-3	0.397	1.621	1.570	1.534	1.495	1.524	1.248	96	93	90	92	70	> 2.23E-5	> 2.23E-5	> 2.23E-5
DU-145	0.309	1.123	1.062	1.157	1.084	1.072	0.994	93	104	95	94	84	> 2.23E-5	> 2.23E-5	> 2.23E-5
Breast Cancer															
MCF7	0.204	1.049	0.971	1.018	1.011	1.077	0.692	91	96	96	103	58	> 2.23E-5	> 2.23E-5	> 2.23E-5
MDA-MB-231/ATCC	0.449	1.138	1.073	1.133	1.058	1.033	0.921	91	99	88	85	68	> 2.23E-5	> 2.23E-5	> 2.23E-5
HS 578T	0.514	1.108	1.057	1.092	1.043	1.046	1.028	91	97	89	89	86	> 2.23E-5	> 2.23E-5	> 2.23E-5
BT-549	0.792	1.372	1.355	1.378	1.362	1.404	1.449	97	101	98	105	113	> 2.23E-5	> 2.23E-5	> 2.23E-5
T-47D	0.443	0.940	0.904	0.925	0.916	0.933	0.880	93	97	95	99	88	> 2.23E-5	> 2.23E-5	> 2.23E-5
MDA-MB-468	0.536	1.361	1.255	1.336	1.247	0.994	0.487	87	97	86	56	-9	2.71E-6	1.61E-5	> 2.23E-5

Table S10. NCI 60-cell line results for **13**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 751839 / 1	Experiment ID : 0912NS69	Test Type : 08	Units : Molar
Report Date : February 01, 2010	Test Date : December 14, 2009	QNS :	MC :
COMI : PC 1009 (92198)	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-8.7	-7.7	-6.7	-5.7	-4.7	-8.7	-7.7	-6.7	-5.7	-4.7	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.349	1.583	1.605	1.458	0.599	0.542	0.524	102	90	20	16	14	7.78E-8	> 2.08E-5	> 2.08E-5
HL-60(TB)	0.717	2.326	2.137	2.052	0.585	0.491	0.482	88	83	-18	-32	-33	4.40E-8	1.37E-7	> 2.08E-5
K-562	0.257	1.337	1.141	1.088	0.736	0.544	0.271	82	77	44	27	1	1.40E-7	> 2.08E-5	> 2.08E-5
MOLT-4	0.598	1.723	1.731	1.533	0.977	0.656	0.516	101	83	34	5	-14	9.70E-8	3.89E-6	> 2.08E-5
RPMI-8226	0.685	2.244	2.228	2.043	0.967	0.763	0.683	99	87	18	5	.	7.17E-8	1.83E-5	> 2.08E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.353	1.074	1.118	0.820	0.279	0.251	0.247	106	65	-21	-29	-30	3.09E-8	1.18E-7	> 2.08E-5
EKVX	0.633	1.567	1.656	1.573	0.728	0.635	0.470	110	101	10	.	-26	7.55E-8	2.12E-6	> 2.08E-5
HOP-62	0.259	0.766	0.827	0.790	0.231	0.197	0.164	112	105	-11	-24	-37	6.20E-8	1.68E-7	> 2.08E-5
HOP-92	1.146	1.967	1.941	1.966	0.487	0.669	0.872	97	100	-58	-42	-24	4.31E-8	8.97E-8	.
NCI-H226	0.670	1.461	1.414	1.351	0.793	0.644	0.576	94	86	16	-4	-14	6.75E-8	1.31E-6	> 2.08E-5
NCI-H23	0.402	1.268	1.236	1.245	0.663	0.563	0.472	96	97	30	19	8	1.05E-7	> 2.08E-5	> 2.08E-5
NCI-H322M	0.461	0.875	0.910	0.856	0.604	0.519	0.446	108	96	34	14	-3	1.16E-7	1.33E-5	> 2.08E-5
NCI-H460	0.241	2.027	1.862	1.200	0.453	0.353	0.191	91	54	12	6	-21	2.54E-8	3.53E-6	> 2.08E-5
NCI-H522	0.593	1.325	1.314	1.263	0.591	0.260	0.201	98	92	.	-56	-66	5.89E-8	2.06E-7	1.61E-6
Colon Cancer															
COLO 205	0.195	1.172	1.162	0.804	0.214	0.307	0.336	99	62	2	11	14	3.32E-8	> 2.08E-5	> 2.08E-5
HCC-2998	0.747	1.716	1.750	1.620	0.621	0.395	0.210	103	90	-17	-47	-72	4.93E-8	1.45E-7	2.70E-6
HCT-116	0.239	1.618	1.584	1.379	0.555	0.394	0.292	98	83	23	11	4	7.33E-8	> 2.08E-5	> 2.08E-5
HCT-15	0.243	1.683	1.584	1.569	1.402	0.644	0.444	93	92	80	28	14	7.89E-7	> 2.08E-5	> 2.08E-5
HT29	0.153	0.626	0.610	0.440	0.140	0.107	0.123	97	61	-9	-30	-20	2.96E-8	1.55E-7	> 2.08E-5
KM12	0.247	1.273	1.233	1.112	0.673	0.496	0.349	96	84	42	24	10	1.32E-7	> 2.08E-5	> 2.08E-5
SW-620	0.205	1.204	1.118	0.817	0.399	0.292	0.273	91	61	19	9	7	3.87E-8	> 2.08E-5	> 2.08E-5
CNS Cancer															
SF-268	0.389	1.189	1.170	1.125	0.249	0.211	0.245	98	92	-36	-46	-37	4.42E-8	1.09E-7	> 2.08E-5
SF-295	0.751	1.251	1.212	1.129	0.446	0.350	0.315	92	76	-41	-53	-58	3.45E-8	9.29E-8	1.11E-6
SF-539	0.602	1.924	1.894	1.920	0.740	0.581	0.418	98	100	10	-3	-31	7.49E-8	1.17E-6	> 2.08E-5
SNB-19	0.492	1.645	1.560	1.417	0.868	0.724	0.676	93	80	33	20	16	8.97E-8	> 2.08E-5	> 2.08E-5
SNB-75	0.519	1.003	0.937	0.858	0.080	0.045	0.090	86	70	-85	-91	-83	2.80E-8	5.90E-8	1.24E-7
U251	0.273	1.184	1.134	0.937	0.243	0.196	0.212	95	73	-11	-28	-22	3.90E-8	1.54E-7	> 2.08E-5
Melanoma															
LOX IMVI	0.105	0.588	0.534	0.181	0.099	0.101	0.066	89	16	-6	-4	-38	7.06E-9	1.12E-7	> 2.08E-5
MALME-3M	0.844	1.496	1.446	1.455	0.742	0.671	0.617	92	94	-12	-20	-27	5.39E-8	1.60E-7	> 2.08E-5
M14	0.297	1.004	0.981	0.942	0.356	0.266	0.161	97	91	8	-10	-46	6.54E-8	5.79E-7	> 2.08E-5
MDA-MB-435	0.349	1.179	1.160	1.032	0.471	0.379	0.300	98	82	15	4	-14	6.25E-8	3.32E-6	> 2.08E-5
SK-MEL-2	0.714	1.285	1.355	1.171	0.411	0.236	0.192	112	80	-42	-67	-73	3.66E-8	9.37E-8	4.22E-7
SK-MEL-28	0.451	1.302	1.321	1.247	0.387	0.323	0.340	102	94	-14	-28	-25	5.28E-8	1.54E-7	> 2.08E-5
SK-MEL-5	0.409	2.204	2.157	2.021	0.501	0.285	0.048	97	90	5	-30	-88	6.13E-8	2.89E-7	4.53E-6
UACC-257	0.559	0.953	0.938	0.868	0.386	0.335	0.311	96	78	-31	-40	-44	3.78E-8	1.08E-7	> 2.08E-5
UACC-62	0.662	1.886	1.844	1.731	1.100	0.845	0.385	97	87	36	15	-42	1.10E-7	3.81E-6	> 2.08E-5
Ovarian Cancer															
IGROV1	0.479	0.901	0.899	0.777	0.210	0.237	0.197	100	71	-56	-51	-59	3.02E-8	7.50E-8	1.86E-7
OVCAR-3	0.536	1.288	1.326	1.266	0.319	0.247	0.216	105	97	-40	-54	-60	4.57E-8	1.06E-7	1.05E-6
OVCAR-4	0.347	0.563	0.552	0.494	0.284	0.254	0.281	95	68	-18	-27	-19	3.36E-8	1.28E-7	> 2.08E-5
OVCAR-5	0.488	1.171	1.139	1.195	0.767	0.641	0.671	95	104	41	22	27	1.48E-7	> 2.08E-5	> 2.08E-5
OVCAR-8	0.228	0.781	0.736	0.741	0.372	0.263	0.143	92	93	26	6	-37	9.10E-8	2.89E-6	> 2.08E-5
NCI/ADR-RES	0.283	0.933	0.950	0.917	0.800	0.514	0.368	103	98	80	35	13	9.75E-7	> 2.08E-5	> 2.08E-5
SK-OV-3	0.460	1.080	1.076	1.093	0.407	0.356	0.268	99	102	-12	-23	-42	5.97E-8	1.65E-7	> 2.08E-5
Renal Cancer															
786-0	0.387	1.402	1.397	1.259	0.312	0.189	0.175	100	86	-19	-51	-55	4.56E-8	1.36E-7	1.89E-6
A498	0.736	1.636	1.290	1.111	0.141	0.129	0.185	62	42	-81	-83	-75	7.89E-9	4.55E-8	1.16E-7
ACHN	0.348	1.536	1.532	1.489	0.637	0.415	0.481	100	96	24	6	11	9.12E-8	> 2.08E-5	> 2.08E-5
CAKI-1	0.678	0.970	0.972	1.041	0.296	0.122	0.211	101	124	-56	-82	-69	5.36E-8	1.01E-7	1.92E-7
RXF 393	0.649	1.251	1.203	1.156	0.287	0.246	0.076	92	84	-56	-62	-88	3.65E-8	8.30E-8	1.89E-7
SN12C	0.519	1.800	1.901	1.728	1.028	0.756	0.634	108	94	40	18	9	1.35E-7	> 2.08E-5	> 2.08E-5
TK-10	0.374	0.854	0.871	0.817	0.282	0.162	0.133	103	92	-25	-57	-64	4.78E-8	1.28E-7	1.29E-6
UO-31	0.569	1.186	1.145	1.124	0.515	0.152	0.228	93	90	-10	-73	-60	5.24E-8	1.67E-7	8.95E-7
Prostate Cancer															
PC-3	0.397	1.562	1.569	1.464	0.836	0.587	0.485	101	92	38	16	8	1.23E-7	> 2.08E-5	> 2.08E-5
DU-145	0.309	1.071	1.100	1.044	0.409	0.343	0.272	104	96	13	4	-12	7.50E-8	3.84E-6	> 2.08E-5
Breast Cancer															
MCF7	0.204	0.931	0.909	0.663	0.336	0.293	0.235	97	63	18	12	4	4.06E-8	> 2.08E-5	> 2.08E-5
MDA-MB-231/ATCC	0.449	1.112	1.138	1.063	0.621	0.508	0.388	104	93	26	9	-14	9.04E-8	5.15E-6	> 2.08E-5
HS 578T	0.514	1.153	1.275	1.213	0.477	0.397	0.287	119	109	-7	-23	-44	6.72E-8	1.80E-7	> 2.08E-5
BT-549	0.792	1.362	1.373	1.362	0.147	0.082	0.063	102	100	-81	-90	-92	3.92E-8	7.40E-8	1.40E-7
T-47D	0.443	0.919	0.912	0.902	0.563	0.508	0.408	99	96	25	14	-8	9.34E-8	8.84E-6	> 2.08E-5
MDA-MB-468	0.536	1.371	1.318	1.033	0.219	0.202	0.193	94	59	-59	-62	-64	2.50E-8	6.60E-8	1.74E-7

Table S11. NCI 60-cell line results for **14**.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 662466 / 1	Experiment ID : 9306NS84	Test Type : 08	Units : Molar
Report Date : February 04, 2010	Test Date : June 28, 1993	QNS :	MC :
COMI : PC#278	Stain Reagent : SRB Dual-Pass Related	SSPL : K24A	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-9.0	-8.0	-7.0	-6.0	-5.0	-9.0	-8.0	-7.0	-6.0	-5.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.347	1.173	1.224	1.219	1.271	1.155	0.357	106	106	112	98	1	3.13E-6	> 1.00E-5	> 1.00E-5
K-562	0.213	1.367	1.412	1.429	1.273	1.226	0.466	104	105	92	88	22	3.75E-6	> 1.00E-5	> 1.00E-5
MOLT-4	0.393	1.349	1.365	1.396	1.427	1.386	0.568	102	105	108	104	18	4.26E-6	> 1.00E-5	> 1.00E-5
RPMI-8226	0.413	1.447	1.459	1.414	1.546	1.412	0.410	101	97	110	97	-1	3.01E-6	9.80E-6	> 1.00E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.416	1.807	1.824	1.800	1.690	1.688	0.572	101	100	92	91	11	3.29E-6	> 1.00E-5	> 1.00E-5
EKVX	0.621	1.597	1.516	1.556	1.571	1.527	0.760	92	96	97	93	14	3.50E-6	> 1.00E-5	> 1.00E-5
HOP-62	0.608	1.453	1.413	1.385	1.431	1.493	0.655	95	92	98	105	6	3.57E-6	> 1.00E-5	> 1.00E-5
HOP-92	0.668	1.039	1.090	1.120	1.021	1.074	0.545	114	122	95	109	-19	2.91E-6	7.17E-6	> 1.00E-5
NCI-H226	0.612	1.284	1.291	1.336	1.333	1.331	0.913	101	108	107	107	45	8.26E-6	> 1.00E-5	> 1.00E-5
NCI-H23	0.478	1.248	1.236	1.305	1.327	1.271	0.845	99	107	110	103	48	9.08E-6	> 1.00E-5	> 1.00E-5
NCI-H322M	0.636	1.493	1.493	1.456	1.460	1.524	1.165	100	96	96	104	62	> 1.00E-5	> 1.00E-5	> 1.00E-5
NCI-H460	0.253	1.144	1.217	1.165	1.313	1.217	0.292	108	102	119	108	4	3.64E-6	> 1.00E-5	> 1.00E-5
NCI-H522	0.505	1.466	1.319	1.432	1.467	1.473	0.486	85	97	100	101	-4	3.06E-6	9.20E-6	> 1.00E-5
Colon Cancer															
COLO 205	0.346	1.304	1.335	1.285	1.331	1.127	0.346	103	98	103	82	.	2.44E-6	> 1.00E-5	> 1.00E-5
HCC-2998	0.462	1.522	1.503	1.485	1.463	1.424	0.200	98	97	95	91	-57	1.89E-6	4.13E-6	9.01E-6
HCT-116	0.266	1.428	1.463	1.401	1.431	1.409	0.448	103	98	100	98	16	3.84E-6	> 1.00E-5	> 1.00E-5
HCT-15	0.460	1.907	2.008	1.908	1.928	1.878	1.090	107	100	101	98	44	7.61E-6	> 1.00E-5	> 1.00E-5
HT29	0.224	1.161	1.178	1.201	1.176	1.145	0.270	102	104	102	98	5	3.29E-6	> 1.00E-5	> 1.00E-5
KM12	0.355	1.351	1.358	1.292	1.391	1.374	0.661	101	94	104	102	31	5.38E-6	> 1.00E-5	> 1.00E-5
SW-620	0.201	0.984	1.001	0.947	0.914	0.847	0.438	102	95	91	83	30	4.18E-6	> 1.00E-5	> 1.00E-5
CNS Cancer															
SF-268	0.585	1.492	1.539	1.561	1.579	1.568	0.820	105	108	110	108	26	5.09E-6	> 1.00E-5	> 1.00E-5
SF-295	0.580	1.695	1.617	1.681	1.660	1.619	0.988	93	99	97	93	37	5.78E-6	> 1.00E-5	> 1.00E-5
SF-539	0.500	1.143	1.151	1.095	1.147	1.117	0.307	101	93	101	96	-39	2.19E-6	5.16E-6	> 1.00E-5
SNB-19	0.754	1.561	1.631	1.561	1.544	1.583	1.421	109	100	98	103	83	> 1.00E-5	> 1.00E-5	> 1.00E-5
SNB-75	0.625	0.979	1.008	1.005	1.037	1.013	0.287	108	107	116	110	-54	2.31E-6	4.67E-6	9.43E-6
U251	0.347	1.378	1.375	1.293	1.315	1.304	0.451	100	92	94	93	10	3.29E-6	> 1.00E-5	> 1.00E-5
Melanoma															
MALME-3M	0.656	1.323	1.294	1.312	1.295	1.325	0.947	96	98	96	100	44	7.72E-6	> 1.00E-5	> 1.00E-5
M14	0.225	0.827	0.802	0.676	0.819	0.872	0.405	96	75	99	108	30	5.50E-6	> 1.00E-5	> 1.00E-5
MDA-MB-435	0.409	1.463	1.480	1.484	1.512	1.525	0.697	102	102	105	106	27	5.14E-6	> 1.00E-5	> 1.00E-5
SK-MEL-2	0.632	1.046	1.055	1.084	1.069	1.093	0.397	102	109	106	111	-37	2.59E-6	5.61E-6	> 1.00E-5
SK-MEL-28	0.481	1.152	1.157	1.153	1.161	1.274	0.615	101	100	101	118	20	4.94E-6	> 1.00E-5	> 1.00E-5
SK-MEL-5	0.396	1.953	1.850	1.856	1.843	1.839	0.565	93	94	93	93	11	3.32E-6	> 1.00E-5	> 1.00E-5
UACC-257	0.527	1.403	1.374	1.497	1.498	1.484	0.798	97	111	111	109	31	5.71E-6	> 1.00E-5	> 1.00E-5
Ovarian Cancer															
IGROV1	0.483	1.623	1.642	1.628	1.477	1.494	0.317	102	101	87	89	-35	2.06E-6	5.25E-6	> 1.00E-5
OVCAR-3	0.563	1.497	1.497	1.413	1.434	1.465	0.610	100	91	93	97	5	3.22E-6	> 1.00E-5	> 1.00E-5
OVCAR-4	0.399	1.003	1.015	0.974	1.018	0.952	0.374	102	95	102	92	-6	2.66E-6	8.63E-6	> 1.00E-5
OVCAR-5	0.554	1.277	1.273	1.285	1.272	1.291	0.824	99	101	99	102	37	6.36E-6	> 1.00E-5	> 1.00E-5
OVCAR-8	0.278	1.101	1.075	1.066	1.049	1.003	0.373	97	96	94	88	12	3.15E-6	> 1.00E-5	> 1.00E-5
NCI/ADR-RES	0.392	1.087	1.062	1.054	1.082	1.046	0.710	96	95	99	94	46	8.16E-6	> 1.00E-5	> 1.00E-5
SK-OV-3	0.600	1.211	1.138	1.179	1.161	1.154	0.594	88	95	92	91	-1	2.78E-6	9.73E-6	> 1.00E-5
Renal Cancer															
786-0	0.268	1.199	1.205	1.110	1.178	1.141	0.172	101	90	98	94	-36	2.18E-6	5.30E-6	> 1.00E-5
A498	0.920	1.449	1.380	1.358	1.409	1.448	0.259	87	83	92	100	-72	1.95E-6	3.81E-6	7.46E-6
ACHN	0.668	1.927	1.923	1.937	1.961	1.968	0.642	100	101	103	103	-4	3.14E-6	9.21E-6	> 1.00E-5
CAKI-1	0.553	1.572	1.577	1.627	1.544	1.493	0.954	101	105	97	92	39	6.28E-6	> 1.00E-5	> 1.00E-5
RXF 393	0.556	1.141	1.206	1.202	1.191	1.180	0.595	111	110	109	107	7	3.68E-6	> 1.00E-5	> 1.00E-5
SN12C	0.477	1.370	1.355	1.202	1.346	1.286	0.675	98	81	97	91	22	3.92E-6	> 1.00E-5	> 1.00E-5
TK-10	1.168	1.632	1.655	1.785	1.757	1.857	1.597	105	133	127	149	92	> 1.00E-5	> 1.00E-5	> 1.00E-5
UO-31	0.683	1.979	1.928	1.921	1.911	1.900	0.372	96	96	95	94	-46	2.07E-6	4.72E-6	> 1.00E-5
Prostate Cancer															
PC-3	0.622	1.893	1.773	1.850	1.795	1.695	0.675	91	97	92	84	4	2.68E-6	> 1.00E-5	> 1.00E-5
DU-145	1.129	2.399	2.414	2.428	2.364	2.460	2.069	101	102	97	105	74	> 1.00E-5	> 1.00E-5	> 1.00E-5
Breast Cancer															
MCF7	0.469	1.939	1.866	1.879	1.956	1.876	0.864	95	96	101	96	27	4.62E-6	> 1.00E-5	> 1.00E-5
MDA-MB-231/ATCC	0.363	0.804	0.818	0.679	0.802	0.745	0.314	103	72	99	87	-14	2.32E-6	7.33E-6	> 1.00E-5
HS 578T	0.524	1.269	1.263	1.255	1.303	1.265	0.692	99	98	105	100	23	4.40E-6	> 1.00E-5	> 1.00E-5
MDA-N	0.233	1.024	1.122	0.962	1.071	0.866	0.518	112	92	106	80	36	4.80E-6	> 1.00E-5	> 1.00E-5
BT-549	0.597	1.354	1.319	1.273	1.214	1.277	0.348	95	89	82	90	-42	2.01E-6	4.81E-6	> 1.00E-5
T-47D	0.553	1.089	1.076	1.140	1.213	1.167	0.859	98	110	123	115	57	> 1.00E-5	> 1.00E-5	> 1.00E-5

Table S12. One dose mean graph for **15**.

Developmental Therapeutics Program

One Dose Mean Graph

NSC: D-752380 / 1	Conc: 1.00E-5 Molar	Test Date: Mar 08, 2010
Experiment ID: 1003OS13		Report Date: Apr 16, 2010

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	50.86
HL-60(TB)	78.12
K-562	55.06
MOLT-4	60.28
SR	46.71
Non-Small Cell Lung Cancer	
A549/ATCC	99.42
EKVX	95.71
HOP-62	122.90
NCI-H226	99.82
NCI-H23	95.83
NCI-H322M	117.29
NCI-H460	93.83
NCI-H522	73.66
Colon Cancer	
COLO 205	106.93
HCC-2998	59.01
HCT-116	75.92
HCT-15	101.31
HT29	112.77
KM12	106.71
SW-620	98.47
CNS Cancer	
SF-268	99.44
SF-295	107.31
SF-539	99.86
SNB-19	63.42
SNB-75	101.56
U251	78.85
Melanoma	
LOX IMVI	117.98
MALME-3M	52.18
M14	103.99
MDA-MB-435	94.17
SK-MEL-2	100.56
SK-MEL-28	97.07
SK-MEL-5	81.15
UACC-257	100.97
UACC-62	87.39
Ovarian Cancer	
IGROV1	85.06
OVCAR-3	105.49
OVCAR-5	114.40
OVCAR-8	101.94
SK-OV-3	102.22
Renal Cancer	
786-0	96.97
ACHN	94.28
CAKI-1	74.36
RXF 393	89.36
SN12C	95.43
TK-10	108.68
UO-31	67.62
Prostate Cancer	
PC-3	76.72
DU-145	115.11
Breast Cancer	
MCF7	98.92
MDA-MB-231/ATCC	94.51
HS 578T	123.88
BT-549	93.05
T-47D	72.66
MDA-MB-468	3.07
Mean	90.00
Delta	86.93
Range	120.81



Figure S11. Microfilament effects of **10** in HCT-116 and HeLa cells.



Figure S12. Above water photo of 00101.